

⑮



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 052 016
B1

⑫

EUROPEAN PATENT SPECIFICATION

④⑤ Date of publication of patent specification: 05.09.84

⑤① Int. Cl.³: **C 07 D 471/04, A 61 K 31/47**
// (C07D471/04, 235/00,
221/00)

②① Application number: 81305344.4

②② Date of filing: 11.11.81

⑤④ Carbostyryl compounds, compositions containing same and processes for preparing same.

③⑩ Priority: 11.11.80 JP 159016/80
18.12.80 JP 179950/80

④③ Date of publication of application:
19.05.82 Bulletin 82/20

④⑤ Publication of the grant of the patent:
05.09.84 Bulletin 84/36

⑧④ Designated Contracting States:
BE FR GB

⑤⑧ References cited:
EP-A-0 007 525
EP-A-0 008 014
GB-A-1 473 819
GB-A-2 031 404

⑦③ Proprietor: OTSUKA PHARMACEUTICAL CO.,
LTD.
9, Kandatsukasacho 2-chome
Chiyoda-ku Tokyo 101 (JP)

⑦② Inventor: Michiaki, Tominaga
No. 21-3 Aza Todoroki Yoshinari Ojin-cho
Tokushima-shi Tokushima (JP)
Inventor: Yang, Yung-Hsiung
No. 463-10, Kagasuno Kawauchi-chi
Tokushima-shi Tokushima (JP)
Inventor: Kazuyuki, Nakagawa
No. 774-1 Omatsu Kawauchi-cho
Tokushima-shi Tokushima (JP)
Inventor: Hidenori, Ogawa
No. 463-10, Kagasuno Kawauchi-chi
Tokushima-shi Tokushima (JP)

⑦④ Representative: Pearce, Anthony Richmond
et al
Marks & Clerk Alpha Tower Suffolk Street
Queensway
Birmingham B1 1TT (GB)

EP 0 052 016 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Courier Press, Leamington Spa, England.

0 052 016

Description

BACKGROUND OF THE INVENTION

This invention relates to certain carbostyryl compounds and to pharmaceutically acceptable salts thereof which are useful as cardiostonic agents, processes for preparing the same, and pharmaceutical compositions containing the carbostyryl compounds or salt thereof.

Various carbostyryl compounds are known which have hypotensive, blood platelet coagulation inhibitory or antiallergic activity as described in Japanese Patent published applications (OPI) Nos. 130589/79, 135785/79, 138585/79, 141785/79, 76872/80, 49319/80, 53283/80, 53284/ and 83781/80.

Further, EP—A1—7525 and EP—A1—8014 describe isoquinoline compounds which have cardiac and circulatory activities.

However, the carbostyryl compounds of this invention are structurally different from the conventional carbostyryl and isoquinoline compounds.


SUMMARY OF THE INVENTION

One object of this invention is to provide carbostyryl compounds having a cardiostonic activity.

Another object of this invention is to provide a pharmaceutical composition containing the carbostyryl compound in a cardiostonically effective amount.

A further object of this invention is to provide a process for preparing a carbostyryl compound and its pharmaceutically acceptable salts thereof.

As a result of extensive research this invention has been accomplished which, in one aspect, provides a carbostyryl compound of the formula (I)



(I)

wherein

R¹ represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or a phenyl-lower alkyl group;


R² represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogen atom, or a hydroxy group;

R³ represents a hydrogen atom, a lower alkyl group, a halogen atom, a nitroso group, an amino group which may be substituted with a lower alkyl group, a lower alkanoylamino group, a N,N-di-lower alkylaminomethyl group, a carbamoylmethyl group, a cyanomethyl group, or a carboxymethyl group;

R⁴ and R⁵, which may be the same or different, each represents a hydrogen atom, a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, or a nitro group;

the bonding between the 3- and 4-positions of the carbostyryl nucleus is a single bond or a double bond; and

the position at which the imidazopyridyl group of the formula



is attached to the carbostyryl nucleus is the 5- or 6-position;

with the proviso that when the imidazopyridyl group is attached to the 5-position of the carbostyryl nucleus, R² should not be a hydrogen atom, a lower alkyl group, or a halogen atom; or its pharmaceutically acceptable salt.

0 052 016

In another aspect this invention provides a cardiotonic composition containing a compound of the formula (I) or a pharmaceutically acceptable salt thereof in a cardionically effective amount.

In a further aspect, this invention provides processes for preparing the compounds of the formula (I) and pharmaceutically acceptable salts thereof.

5 The compounds of the formula (I) above and pharmaceutically acceptable salts thereof have heart muscle contraction stimulating effect or positive isotonic effect and coronary blood flow increasing activity, and are useful as a cardiotonic agent for treating heart diseases such as congestive heart failure and the like. They are advantageous in that they do not or only slightly, if any, increase heart beats.

10

DETAILED DESCRIPTION OF THE INVENTION

The term "lower alkyl" as used herein refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a tert-butyl group, a pentyl group, and a hexyl group.

15 The term "phenyl-lower alkyl" as used herein refers to a phenyl-lower alkyl group having a straight or branched chain alkyl group having 1 to 6 carbon atoms in the alkyl moiety such as a benzyl group, a 2-phenylethyl group, a 1-phenylethyl group, a 3-phenylpropyl group, a 4-phenylbutyl group, a 1, 1-dimethyl-2-phenylethyl group, a 5-phenylpentyl group, a 6-phenylhexyl group, and a 2-methyl-3-phenylpropyl group.

20 The term "lower alkenyl" as used herein refers to a straight or branched chain alkenyl group having 2 to 6 carbon atoms such as a vinyl group, an allyl group, a crotyl group, a 1-methallyl group, a 3-butenyl group, a 2-pentenyl group, 3-pentenyl group, a 4-pentenyl group, a 2-methyl-3-butenyl group, a 1-methyl-3-butenyl group, a 2-hexenyl group, a 3-hexenyl group, a 4-hexenyl group, a 5-hexenyl group, a 2-methyl-4-pentenyl group, a 1-methyl-4-pentenyl group, a 2-methyl-3-pentenyl group and a 1-methyl-3-pentenyl group.

25 The term "lower alkynyl" as used herein refers to a straight or branched alkynyl group having 2 to 6 carbon atoms such as an ethynyl group, a 2-propynyl group, a 1-propynyl group, a 2-butylnyl group, a 3-butylnyl group, a 2-pentylnyl group, a 3-pentylnyl group, a 4-pentylnyl group, a 2-methyl-3-butylnyl group, a 1-methyl-3-butylnyl group, a 2-hexynyl group, a 3-hexynyl group, a 4-hexynyl group, a 5-hexynyl group, a 2-methyl-4-pentylnyl group, a 1-methyl-4-pentylnyl group, a 2-methyl-3-pentylnyl group and a 1-methyl-3-pentylnyl group.

The term "halogen" as used herein refers to a halogen atom such as chlorine, bromine, iodine and fluorine.

35 The term "amino group which may be substituted with a lower alkyl group" as used herein refers to an amino group and an amino group substituted with 1 or 2 of a straight or branched chain lower alkyl group having 1 to 6 carbon atoms such as a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, a tert-butylamino group, a pentylamino group, a hexylamino group, an N,N-dimethylamino group, an N,N-diethylamino group, an N-methyl-N-ethylamino group, an N-methyl-N-propylamino group, an N-ethyl-N-isopropylamino group, an N,N-dipropylamino group, an N-methyl-N-butylamino group, an N-ethyl-N-tert-butylamino group, and N,N-dibutylamino group, an N-methyl-N-pentylamino group, an N-propyl-N-pentylamino group, an N,N-dipentylamino group, an N-methyl-N-hexylamino group, an N-butyl-N-hexylamino group, and an N,N-dihexylamino group.

40 The term "N,N-di-lower alkylaminomethyl" as used herein refers to an N,N-di-lower alkylaminomethyl group having a straight or branched chain alkyl group having 1 to 6 carbon atoms in each alkyl moiety thereof such as an N,N-dimethylaminomethyl group, an N-methyl-N-ethylaminomethyl group, an N,N-diethylaminomethyl group, an N-methyl-N-propylaminomethyl group, an N-ethyl-N-isopropylaminomethyl group, an N,N-dipropylaminomethyl group, an N-methyl-N-butylaminomethyl group, an N-ethyl-N-tert-butylaminomethyl group, an N,N-dibutylaminomethyl group, an N-methyl-N-pentylaminomethyl group, an N-propyl-N-pentylaminomethyl group, an N,N-dipentylaminomethyl group, an N-methyl-N-hexylaminomethyl group, an N-butyl-N-hexylaminomethyl group and an N,N-dihexylaminomethyl group.

The term "lower alkanoylamino" as used herein refers to a straight or branched chain lower alkanoylamino group having 1 to 6 carbon atoms such as a formamido group, an acetamido group, a propionylamino group, a butyrylamino group.

55 an isobutyrylamino group, a valerylamino group, an isovalerylamino group and a hexanoylamino group.

The term "lower alkoxy" as used herein refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, a tert-butoxy group, a pentyloxy group and a hexyloxy group.


60

65

O 052 016

The compounds of this invention of the formula (I) can be prepared by various alternative procedures. A preferred example thereof is a process according to Reaction Scheme-1 below.

Reaction Scheme - 1



In the above formulae, X¹ represents a halogen atom and R⁶ represents a hydrogen atom or a lower alkyl group and R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above.

In the formula (II), examples of the halogen atom represented by X¹ include chlorine, fluorine, bromine and iodine.

The reaction between the compound of the formula (II) and the compound of the formula (III) which is a known compound can be carried out in the absence of solvents or in the presence of an appropriate solvent, preferably in the presence of a solvent. There is no particular limitation on the solvents and any solvents that do not affect the reaction adversely can be used.

Examples of the suitable inert solvent which can be used include water, lower alcohols such as methanol, ethanol, isopropanol and butanol, aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as dioxane and tetrahydrofuran, nitriles such as acetonitrile and propionitrile, dimethyl sulfoxide, dimethylformamide and hexamethylphosphoric triamide.

In the above reaction, the proportion of the compound of the formula (III) to the compound of the formula (II) is not particularly limited, and can be varied broadly. Usually the reaction is carried out using at least an equimolar amount, and preferably from 1.5 to 3 moles, of the compound of the formula (III) per mole of the compound of the formula (II).


Further, the reaction can be carried out in the presence of a basic compound which is used conventionally as a dehydrohalogenating agent.

Examples of suitable basic compound include inorganic basic compounds, for example, metal carbonates or hydrogen-carbonates such as sodium carbonate, potassium carbonate and sodium hydrogencarbonate, organic basic compounds such as triethylamine, pyridine, and N,N-dimethylaniline.

The reaction can be carried out usually at a temperature of from about room temperature to 150°C and completed generally in about 1 to 10 hours.

Of the compounds of the formula (I), those in which the bonding between the 3- and 4-positions of the carbostyryl nucleus is a single bond (i.e., compounds of the formula (Ia)) and those in which such a bonding is a double bond (i.e., compounds of the formula (Ib)) can be converted to each other by reduction reaction or dehydrogenation reaction as shown in Reaction Scheme-2 below.

Reaction Scheme - 2



O 052 016

Dehydrogenation reaction of the compound of the formula (Ia) can be carried out in an appropriate solvent using a dehydrogenating agent. Examples of suitable dehydrogenating agent include benzoquinones such as 2,3-dichloro-5,6-dicyanobenzoquinone and chloranil (2,3,5,6-tetrachlorobenzoquinone), halogenating agents such as N-bromosuccinimide, N-chlorosuccinimide and bromine, dehydrogenating agents such as sulfur and selenium dioxide, dehydrogenation metal catalysts such as palladium-carbon, palladium black, platinum black, palladium oxide and Raney nickel.

When benzoquinones and halogenating agents are used as a dehydrogenating agent, the amount of the dehydrogenating agent which is used is not limited particularly and can be varied widely. Usually, 1 to 5 moles, preferably 1 to 2 moles, of the dehydrogenating agent per mole of the compound of the formula (Ia) is used. When the dehydrogenating metal catalysts are used, they are used in ordinary catalytic amounts. For example, the catalysts are used in about the same weight as the compound of the formula (Ia) to be used.

Examples of suitable solvent include water, ketones such as acetone, ethers such as dioxane, tetrahydrofuran, methoxyethanol and dimethoxyethane, aromatic hydrocarbons such as benzene, toluene, xylene, phenetole, tetralin, cumene and chlorobenzene, halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform and carbon tetrachloride, alcohols such as methanol, ethanol, isopropanol, butanol, tert-butanol, amyl alcohol and hexanol, protic polar solvents such as acetic acid, aprotic polar solvents such as DMF, DMSO, Hexamethylphosphoric triamide.


The reaction can be carried out usually at room temperature to 300°C, preferably at room temperature to 200°C and completed generally in about 1 to 40 hours.

Reduction reaction of the compounds of the formula (Ib) can proceed under conventional conditions for catalytic reductions. Examples of the catalyst which can be used include metals such as palladium, palladium black, palladium-carbon, platinum, platinum oxide, platinum black and Raney nickel, in catalytic amounts usually used.

As for the solvent there can be used, for example, water, methanol, ethanol, isopropanol, dioxane, THF, hexane, cyclohexane, ethyl acetate, and acetic acid.

The reduction reaction can be carried out at 0 to 100°C, preferably room temperature to 70°C and either at atmospheric pressure or under pressure. Usually, the reaction is carried out at atmospheric to 10 kg/cm², preferably atmospheric to 5 kg/cm².

Reaction Scheme - 3



In the above formulae, R^{1'} represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a phenyl-lower alkyl group, X² represents a halogen atom, and R², R³, R⁴ and R⁵ have the same meanings as defined above.

According to Reaction Scheme-3, in the case where the groups represented by R², R³, R⁴ and R⁵ are each in an inert group, a compound of the formula (I) in which R¹ represents a hydrogen atom or a compound of the formula (Ic) can be converted to a corresponding compound of the formula (I) in which R¹ represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a phenyl-lower alkyl group or a compound of the formula (Id).

More particularly, a compound of the formula (Ic) can be reacted with a basic component, for example, sodium hydride, potassium hydride, sodium amide, potassium amide, alkali metals such as sodium metal and potassium metal, to convert the compound of the formula (Ic) to its alkali metal salt in which the nitrogen atom at the 1-position of the carbostyryl nucleus takes part in salt formation. This reaction can be carried out in an appropriate solvent, for example, aromatic hydrocarbons such as benzene, toluene and xylene, saturated hydrocarbons such as n-hexane and cyclohexane, ethers such as diethyl ether, diethylene glycol dimethyl ether, 1,2-dimethoxyethane and dioxane, aprotic polar solvents such as dimethylformamide, hexamethylphosphoric triamide dimethyl sulfoxide with aprotic solvents being preferred.

The reaction can be carried out at a temperature of 0 to 200°C, preferably room temperature to 50°C.

O 052 016


The alkali metal salt of the compound of the formula (Ic) thus obtained can be reacted with a halide of the formula (IV) in a conventional manner. This reaction can proceed advantageously in an appropriate solvent which can be used in converting a compound of the formula (Ic) to its alkali metal salt, usually, at a temperature of about 0 to 70°C, preferably 0°C to room temperature.

Proportion of the basic compound to be used to the compound of the formula (Ic) is usually 1 to 5 moles, preferably 1 to 3 moles, of the basic compound per mole of the compound of the formula (Ic). On the other hand, proportion of the halide of the compound of the formula (IV) to be used to the compound of the formula (Ic) is usually 1 to 5 moles, preferably 1 to 3 moles, of the halide of the formula (IV) per mole of the compound of the formula (Ic). The reaction can be completed in about 0.5 to 15 hours.

The carbostyryl compounds of the formula (II) which can be used as a starting compound in Reaction Scheme-1 can readily be prepared in various processes. For example, they can be prepared according to processes shown in Reaction Schemes-4, -5, -6, and -7 below.

Of the compounds of the formula (I), those in which R² represents a hydroxy group or a lower alkoxy group can be prepared according to Reaction Scheme-4 below.

Reaction Scheme - 4



In the above formula, R¹, R⁶, X¹ and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, X³ represents a halogen atom, and R⁷ represents a hydrogen atom or a lower alkyl group.

In Reaction Scheme-4 above, reaction between the carbostyryl derivative of the formula (IV) and the halogenoalkanoyl halide derivative of the formula (V) can be carried out usually in the presence of a Lewis acid as a catalyst.

In the above reaction, any conventionally used Lewis acid can be used advantageously, for example, aluminum chloride, iron chloride, zinc chloride and tin chloride.

The reaction can be carried out either in the absence of solvents or in the presence of an

O 052 016

appropriate inert solvent for example, carbon disulfide, methylene chloride, 1,2-dichloroethane, chlorobenzene, nitrobenzene, diethyl ether and dioxane.

The reaction can be carried out usually at about room temperature to 150°C, preferably room temperature to 100°C.

5 Proportion of the compound of the formula (V) to the compound of formula (IV) is usually equimolar amount to a large excess amount, preferably 2 to 6.5 moles, of the compound of the formula (V) per mole of the compound of the formula (IV).

Alternatively, a compound of the formula (IIa) can be prepared by reacting a compound of the formula (IV) with a compound of the formula (VI) instead of a compound of the formula (V) to form a
10 compound of the formula (VII) and then halogenating this compound.

In the reaction between the compound of the formula (IV) and the compound of the formula (VI) the same reaction conditions as those under which the compound of the formula (IV) and the compound of the formula (V) is reacted.

Halogenation of the compound of formula (VII) can be carried out in the presence of a
15 halogenating agent conventionally used. In the reaction various known halogenating agent can be used. For example, there can be illustrated halogens such as bromine, chlorine, etc., N-halogenosuccinimides such as N-bromosuccinimide and N-chlorosuccinimide.

Proportion of the halogenating agent to the compound of the formula (VII) is usually about 1 to 10 moles, preferably 1 to 5 moles, of the halogenating agent per mole of the compound of the formula
20 (VII).

Examples of the solvents which can be used in the halogenation reaction of the compound of the formula (VIII) include halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform and carbon tetrachloride, organic acids such as acetic acid and propionic acid.

The reaction can readily proceed usually under ice cooling or at a temperature up to the boiling
25 point of the solvent used, preferably room temperature to 40°C and can be completed generally in about 1 to 10 hours. In the reaction a radical reaction initiator, such as benzoyl peroxide or hydrogen peroxide, may be used.

30

35

40

45

50


55

60

65

0 052 016

Reaction Scheme - 5



In the above formulae, R^8 represents a lower alkanoyl group, R^9 represents a lower alkyl group, R^1 , R^3 , R^7 , X^1 and the bonding between the 3- and 4-positions of the carbostyril nucleus have the same meanings as defined above.

Acylation reaction of the compound of the formula (VIII) can be carried out by reacting the compound of the formula (VIII) with a lower alkanoyl anhydride or its acid halide without solvent or in a solvent such as pyridine, benzene, nitrobenzene, ether, acetone or dioxane, in the presence of a basic compound, e.g. an alkali metal carbonate such as sodium carbonate or potassium carbonate, an organic

0 052.016

base such as triethylamine, N,N-dimethylaniline or 1,5-diazabicyclo[5,4,0]undecene-5 (DBU), or an acidic compound such as sulfuric acid or p-toluenesulfonic acid.

Proportion of the lower alkanolic anhydride or its acid halide to be used to the compound of the formula (VIII) is usually at least 1 mole to a large excess amount, preferably 1 to 10 moles, of the anhydride or halide per mole of the compound of the formula (VIII).

The acylation reaction can proceed usually at a temperature of from about -10°C to 150°C , preferably 0 to 100°C and be completed generally in about 10 minutes to 10 hours.

Nitration reaction of the compound of the formula (IX) can be carried out without solvent or in a solvent such as acetic acid, acetic anhydride or sulfuric acid, in the presence of a nitration agent such as fuming nitric acid, concentrated nitric acid, a mixed acid (a mixture of sulfuric acid, fuming sulfuric acid, phosphoric acid or acetic anhydride and nitric acid), a combination of an alkali metal nitrate and sulfuric acid, a mixed acid anhydride of an organic acid with nitric acid such as acetyl nitrate or benzoyl nitrate, a combination of nitrogen pentoxide or nitric acid and silver nitrate, a combination of acetone cyanohydrin nitrate or alkyl nitrate and sulfuric acid or polyphosphoric acid.

The amount of nitration agent to be used is usually 1 to 1.5 moles per mole of the compound of the formula (IX).

The reaction can proceed usually at about -10 to 50°C and can be completed generally in about 1 to 10 hours.

Hydrolysis reaction of the compound of the formula (X) can be carried out in the absence of solvents or in a suitable solvent such as water, methanol, ethanol, isopropanol, acetic acid using an acid or an alkali. Examples of suitable acid include hydrochloric acid and sulfuric acid, and examples of alkali include potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate and sodium hydrogencarbonate.

The amounts of the acid and alkali are at least 1 mole per mole of the compound of the formula (X), respectively. Usually, they are used in a large excess amount relative to the compound of the formula (X). The reaction can be carried out usually at a temperature of about room temperature to 100°C and completed generally in about 0.5 to 5 hours.

Alkylation reaction of the compound of the formula (XI) can be carried out in the presence of a basic compound using a conventional alkylating agent. Examples of suitable basic compound include alkali metals such as sodium metal and potassium metal, and hydroxides, carbonates, bicarbonates and alcoholates thereof, and amines such as pyridine, piperidine. As for the alkylating agent, there can be illustrated alkyl halides such as alkyl iodide (e.g. methyl iodide), alkyl chloride, alkyl bromide (e.g. methyl bromide), and dialkyl sulfates such as dimethyl sulfate and diethyl sulfate.

The reaction can proceed advantageously in a suitable solvent. Examples of suitable solvent include water, lower alcohols such as methanol, ethanol, isopropanol, n-butanol ketones such as acetone, methyl ethyl ketone.

The alkylating agent is used usually in from at least equimolar amount to a large excess amount, preferably 1 to 2 moles per mole of the compound of the formula (XI).

The reaction can proceed with ease at a temperature of from about room temperature to the boiling point of the solvent to be used. Generally, it can be carried out with heating.

Reduction reaction of the compound of the formula (XII) or (XI) can be carried out with ease by subjecting the compound of the formula (XII) or (XI) to catalytic reductions in a solvent such as water, acetic acid, methanol, ethanol, diethyl ether dioxane, in the presence of a catalyst such as palladium black, palladium-carbon, platinum oxide, platinum black, Raney nickel, usually at room temperature under atmospheric pressure, or using a combination of iron, zinc, tin or stannous chloride and an acid (e.g., formic acid, acetic acid, hydrochloric acid, phosphoric acid, sulfuric acid), a combination of iron, ferrous sulfate, zinc or tin and an alkali (e.g., alkali metal hydroxides, alkali metal carbonates, ammonia), sulfates, sodium dithionite sulfites.

Diazotization reaction of the compound of the formula (XIII) or reduction product of the compound of the formula (XI) can be carried out in an aqueous solution using sodium nitrite and hydrochloric acid or sulfuric acid at a temperature of from about -30°C to room temperature for about 1 to 3 hours.

The diazonium salt of the compound of the formula (XI) or (XIII) can further be reacted with a compound of the formula (XIV) to form a compound of the formula (XV). The amount of the compound of the formula (XIV) to be used is usually about 1 to 5 moles, preferably 1 to 2 moles, per mole of the diazonium salt.

The reaction can be carried out advantageously in the presence of a buffering agent such as sodium acetate, sodium carbonate, and calcium carbonate, and sodium sulfite and copper sulfate as a catalyst usually at 0 to 40°C for about 1 to 5 hours.

Halogenation reaction of the compound of the formula (XV) can be carried out using a halogenating agent such as a halogen, e.g. bromine or chlorine, or an N-halogenosuccinimide e.g. N-bromosuccinimide or N-chlorosuccinimide.

Proportion of the halogenating agent to the compound of the formula (XV) is usually 1 to 10 moles, preferably 1 to 5 moles, of the halogenating agent per mole of the compound of the formula (XV).

0 052 016

Examples of suitable solvent which can be used in the reaction include halogenated alkanes such as dichloromethane, dichloroethane, chloroform and carbon tetrachloride.

The reaction can proceed with ease under ice cooling or at a temperature of up to the boiling point of the solvent used, preferably at room temperature to 40°C and can be continued usually for about 1 to 10 hours. In the reaction, a radical reaction initiator such as a peroxide, e.g. benzoyl peroxide or hydrogen peroxide, may be used.


Alternatively, after the diazotization of the compound of the formula (XI) or (XIII), a compound of the following formula



wherein R³ and X¹ have the same meanings as defined above, may be used instead of the compound of the formula (XIV), whereby the compound of the formula (IIb) can be prepared from the compound of the formula (XIII) directly. In this case, the same reaction conditions under which the reaction using the compound of the formula is carried out can be used.

Of the compounds of the formula (XV) or (IIb), those in which R⁷ represents a hydrogen atom can be prepared by heating the compound of the formula (XV) or (IIb) in which R⁷ represents a lower alkyl group in a solvent such as water or dioxane in the presence of an acidic catalyst such as hydrobromic acid at 80 to 130°C for 30 minutes to 6 hours.

Further, of the compound of the formula (II), those in which R² represents a hydrogen atom, a lower alkyl group or a halogen atom can be prepared according to Reaction Scheme-6 below.



In the above formulae, R¹⁰ represents a hydrogen atom, a lower alkyl group or a halogen atom, X⁴ represents a halogen atom, a hydroxy group or a group of the formula



X⁵ represents a halogen atom, a hydroxy group, or a group of the formula



R¹, R³, X¹ and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above.

0 052 016

The reaction between the compound of the formula (XVI) and the compound of the formula (XVII) and that between the compound of formula (XVI) and the compound of the formula (XVIII) are called Friedel Crafts reaction, which can be carried out in a solvent in the presence of a Lewis acid.

Examples of suitable solvent include carbon disulfide, nitrobenzene, chlorobenzene, dichloromethane, dichloroethane, trichloroethane and tetrachloroethane. As for the Lewis acid, any conventionally used Lewis acids can be employed, for example, aluminum chloride, zinc chloride, iron chloride, tin chloride, boron tribromide, boron trifluoride and concentrated sulfuric acid.

The amount of Lewis acid to be used is not particularly limited and can be varied broadly. Usually, about 2 to 6 moles, preferably 3 to 4 moles, of Lewis acid per mole of the compound of the formula (XVI) can be used.


The compound of the formula (XVII) and the compound of the formula (XVIII) each can be used in an amount of usually at least 1 mole, preferably about 1 to 2 moles, per mole of the compound of the formula (XVI).

The reaction temperature can be selected appropriately depending on other conditions. Usually, the reaction is carried out at about 0 to 120°C, preferably 20 to 70°C. The reaction time is varied broadly depending upon starting materials, catalysts, reaction temperatures and the like conditions. Usually, the reaction is completed in about 0.5 to 6 hours.

Halogenation reaction of the compound of the formula (XIX) can be carried out under the same conditions as those under which the halogenation of the compound of the formula (XV) is carried out.

Further, of the compounds of the formula (I), those in which R³ represents a halogen atom, a nitroso group, an amino group, a lower alkylamino group, an N,N-di-lower alkylamino group, a lower alkanoylamino group, an N,N-di-lower alkylaminomethyl group, a carbamoylmethyl group, a cyanomethyl group or carboxymethyl group can be prepared from the compound of the formula (IA) in which R⁶ represents a hydrogen atom (i.e., compound of the formula (Ie)) according to Reaction Schemes 7 to 11 below.

Reaction Scheme -7



In the above formulae, R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above and X⁶ represents a halogen atom.

According to Reaction Scheme-7, the compound of the formula (If) can be prepared by halogenating the compound of the formula (Ie) in a conventional solvent in the presence of a halogenating agent. In the reaction, any conventional halogenating agent can be used. For example, halogens such as chlorine, bromine, iodine, fluorine, phosphorus oxychloride, phosphorus oxybromide, phosphorus pentachloride, phosphorus pentabromide, phosphorus trichloride and thionyl chloride can be used.


Proportion of the halogenating agent to the compound of the formula (Ie) is not limited particularly and can be varied broadly. Usually, 1 to 10 moles, preferably 1 to 1.5 moles, of the halogenating agent per mole of the compound of the formula (Ie) can be used.

Examples of suitable inert solvent include halogenated hydrocarbons such as chloroform, dichloromethane and 1,2-dichloroethane, ethers such as diethyl ether dioxane, and organic acids such as acetic acid and propionic acid.

O 052 016

The halogenation reaction can be carried out under ice cooling or at a temperature of about 0 to 100°C, preferably room temperature to 50°C for about 1 to 12 hours.

Reaction Scheme—8



In the above formulae, R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbofuran nucleus have the same meanings as defined above.

According to Reaction Scheme-8, of the compounds of the formula (I) in which R³ represents a nitroso group (i.e., compound of the formula (Ig)) can be obtained by nitrosylation of the compound of the formula (Ie).

The reaction can be carried out in the absence of solvents or in a suitable inert solvent using a nitrosylating agent and an acid. Any conventional nitrosylating agents can be used. Among them nitrites such as sodium nitrite, potassium nitrite, are preferred. The proportion of the nitrosylating agent to the compound of the formula (Ie) is usually 1 to 2 moles, preferably 1 to 1.2 moles, of the nitrosylating agent per mole of the compound of the formula (Ie).

Examples of suitable acid include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, butyric acid and isobutyric acid, of which the mineral acids are preferred. The acid can be used usually in excess amounts relative to the compound of the formula (Ie) when the reaction is carried out in the absence of solvents. On the other hand, the amount of the acid can be varied broadly and usually is at least 1 mole per mole of the compound of the formula (Ie) when the reaction proceeds in a solvent.

As for the solvent there can be illustrated conventional inert solvents such as water, lower fatty acids e.g. acetic acid, propionic acid, butyric acid, and isobutyric acid, lower fatty acid anhydrides, e.g., acetic anhydride, propionic anhydride, butyric anhydride and isobutyric anhydride, ethers e.g. dioxane and tetrahydrofuran, dimethylformamide and dimethylsulfoxide.

The reaction can be carried out usually at about -30 to 100°C, preferably 0 to 50°C and completed for about 30 minutes to 3 hours.

Reduction of the compound of the formula (Ig) thus formed gives rise to the compounds of the formula (I) in which R³ represents an amino group (i.e., a compound of the formula (Ii)).


This reduction reaction can be carried out using a conventional reducing agent, for example, a mixture of iron and hydrochloric acid, zinc and acetic acid, and tin or stannous chloride and hydrochloric acid in an amount of 1 mole to a large excess amount, preferably 3 to 5 moles, per mole of the compound of the formula (Ig).

Alternatively, the above reactions can be carried out using a suitable hydrogenating catalyst such as palladium black, palladium-carbon, Raney nickel or platinum dioxide. The reaction can proceed advantageously in a solvent, for example, water, a lower alcohol such as methanol, ethanol or isopropanol, or acetic acid. Reaction conditions are not limited particularly and can be varied broadly

0 052 016

depending on the kind and amount of the reducing agent or hydrogenating catalyst. Usually, the reaction is carried out at about 0 to 150°C, preferably 50 to 100°C when a reducing agent is used and at about 0 to 100°C, preferably room temperature at atmospheric pressure of hydrogen gas when a hydrogenating catalyst is used.

Reaction Scheme -9



In the above formulae, R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, R¹¹ represents a hydrogen or a lower alkyl group and R¹² represents a hydrogen atom or a methyl group.

According to Reaction Scheme-9 above, of the compounds of the formula (Ij), those in which R¹¹ represents a lower alkanoylamino group (i.e., compounds of the formula (Ij)) can be prepared by acylating the compound of the formula (II). In the reaction, various reaction conditions under which conventional acylation reactions proceed can be used. For example, the objective compound of the formula (Ij) can be obtained with ease by reacting the compound of the formula (II) with a lower alkanoyl acid or its acid anhydride or halide.

The reaction can be carried out usually in the presence of a basic compound or an acidic compound. Examples of suitable basic compounds include organic bases such as triethylamine, trimethylamine, pyridine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]nonene-5 (DBN), 1,5-diazabicyclo[5.4.0]undecene-5 (DBU), 1,4-diazabicyclo[2.2.2]octane (DABCO), inorganic bases such as potassium carbonate, sodium carbonate, potassium hydrogencarbonate and sodium hydrogencarbonate. On the other hand, examples of suitable acidic compound include mineral acids such as sulfuric acid and hydrochloric acid.

The above reaction can generally proceed in a solvent. Examples of suitable solvent include halogenated carbohydrates such as methylene chloride, chloroform and dichloroethane, aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane, esters such as methyl acetate, ethyl acetate, and aprotic polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide and hexamethylphosphoric triamide.

In the above reaction, the amount of the lower alkanoyl acid or its anhydride or halide is not limited particularly and can be varied broadly. Usually, 1 to 10 moles, preferably 1 to 2 moles, of the lower alkanoyl acid or its anhydride or halide per mole of the compound of the formula (II) can be used. Further, there is no particular limitation on the reaction temperature and reaction time. Usually, the reaction can be carried out at a temperature of about -30°C to 150°C, preferably 0 to 100°C, for about 30 minutes to 12 hours.

Of the compounds of the formula (Ik), those in which R¹² represents a hydrogen atom can be


O 052 016

prepared by reducing the compound of the formula (Ij). The reduction reaction can be carried out under conventional conditions under which the carbonyl group in an amido bond is reduced to form a methylene group. For example, the reaction can proceed in the presence of lithium aluminum halide or sodium borohydride.

5 Of the compounds of the formula (Ik), those in which R^{11} represents a hydrogen atom and R^{12} represents a methyl group can be prepared by reducing a compound of the formula (II). In this reduction reaction can be applied Eschweiler-Clarke Reaction which can usually be carried out with ease by heating the compound of the formula (II) in the presence of formic acid and formalin in the absence of solvents.

10 Proportions of formic acid and formalin to the compound of the formula (II) are not limited particularly and can be varied broadly. Usually, formalin is used in an amount of about 1 to 5 moles, preferably 1 to 1.5 moles, per mole of the compound of the formula (II), while the amount of formic acid is about 1 to 10 moles, preferably 3 to 5 moles per mole of the compound of formula (II). There is no particular limitation on the reaction temperature and time and can be varied broadly. Usually, the
15 reaction is carried out at about room temperature to 150°C , preferably 80 to 120°C for about 3 to 30 hours.

Reaction Scheme - 10



35 In the above formulae, R^1 , R^2 , R^4 , R^5 , X^2 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, and R^{13} represents a lower alkyl group.

Of the compounds of the formula (I), those in which R^3 represents an N,N-di-lower alkylamino group (i.e., compound of the formula (III)) can be prepared by reacting the compound of the formula (II) with a compound of the formula (XX). The reaction can be carried out in the presence of a
40 dehalogenating agent.

As for the dehalogenating agent, various conventional basic compounds can be used. Representative examples of the basic compound include inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate and potassium hydrogen carbonate, alkali metals such as sodium metal and potassium metal, and organic bases such as triethylamine, pyridine and N,N-dimethylaniline.
45

The reaction can proceed either in the absence of solvents or in the presence of a solvent. Any solvents that do not take part in the reaction can be used. For example, alcohols such as methanol, ethanol and propanol, ethers such as diethyl ether, tetrahydrofuran, dioxane and ethylene glycol monomethyl ether, aromatic hydrocarbons such as benzene, toluene, xylene, chlorobenzene, ketones such as acetone and methyl ethyl ketone, and aprotic polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide and hexamethylphosphoric triamide, can be used advantageously.
50

The proportion of the compound of the formula (XX) to the compound of the formula (II) is usually at least 2 moles, preferably 2 to 4 moles, of the compound of the formula (XX) per mole of the compound of the formula (II).

55 When using about 1 mole of the compound of the formula (XX) per mole of the compound of the formula (II) a compound of the formula (I) in which R^3 represents a mono-lower alkylamino group can be prepared. This compound can further be reacted with a compound of the formula




60 wherein $R^{13'}$ represents a lower alkyl group and X^2 represents a halogen atom, to form a compound of the formula (I) in which R^3 represents an N,N-dialkylamino group the alkyl groups of which are different from each other.

65.

0 052 016

The reaction can be carried out usually at about -30 to 100°C , preferably 0 to 50°C and completed generally in about 30 minutes to 12 hours.

Reaction Scheme 11



0 052 016

In the above formulae, R^1 , R^2 , R^4 , R^5 , X^2 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, R^{14} , R^{15} , and R^{16} , which may be the same or different, each represents a lower alkyl group, and M represents an alkali metal.

According to Reaction Scheme-11, of the compounds of the formula (I), those in which R^3 represents an N,N-di-lower alkylaminomethyl group (i.e., compound of the formula (Im)) can be prepared by reacting a compound of the formula (Ie) with a di-lower alkylamine of the formula (XXI) and formalin.

The reaction can be carried out either in the absence of solvents or in the presence of a solvent. As for the solvent any solvents that do not take part in the reaction can be used, for example, water, lower alcohols such as methanol, ethanol and isopropanol, and lower fatty acids such as acetic acid and propionic acid.

Proportions of the compound of the formula (XXI) and formalin to the compound of the formula (Ie) each is usually about 1 to 3 moles, preferably 1 mole, of the compound of the formula (XXI) or formalin per mole of the compound of the formula (Ie).

The reaction can be carried out usually at about 0 to 150°C, preferably room temperature to 100°C and completed generally in about 3 to 6 hours.

Further, a quaternary ammonium salt of the formula (In) can be prepared by reacting the compound of the formula (Im) thus obtained with a compound of the formula (XXII).

The reaction can be carried out either in the absence of solvents or in the presence of a solvent. Any solvents that do not take part in the reaction can be used, for example, water, lower alcohols such as methanol, ethanol and isopropanol, halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride, acetonitrile, propionitrile and N,N-dimethylformamide.

Proportion of the compound of the formula (XXII) to the compound of the formula (Im) is usually 1 mole to a large excess amount, preferably 1 to 2 moles, of the compound of the formula (XXII) per mole of the compound of the formula (Im).

The reaction can be carried out usually at about 0 to 150°C, preferably 30 to 80°C and completed generally in about 30 minutes to 4 hours.

Still further, of the compounds of the formula (I), those in which R^3 represents a carbamoylmethyl group (i.e., compound of the formula (Io)) or a cyano group (i.e., compound of the formula (Ip)) can be prepared by reacting the compound of the formula (In) with a compound of the formula (XXIII).

Each reaction can be carried out in an inert solvent, for example, water, lower alcohols such as methanol, ethanol and isopropanol, and nitriles such as acetonitrile and propionitrile.

Preferred examples of the compound of the formula (XXIII) include potassium cyanide and sodium cyanide.

In preparing the compound of the formula (Io), the compound of the formula (XXIII) is used usually in an equimolar to a large excess amount relative to the compound of the formula (In). Preferably, it is used in an amount of 3 to 4 moles per mole of the compound of the formula (In).

The reaction can be carried out usually at about room temperature to 150°C, preferably 60 to 100°C for about 3 to 12 hours, preferably 5 to 6 hours.

On the other hand, in preparing the compound of the formula (Ip), usually about 1 to 2 moles, preferably 1 mole, of the compound of the formula (XXIII) is reacted with 1 mole of the compound of the formula (In) at about room temperature to 150°C, preferably 60 to 100°C for about 30 minutes to 1 hour.

Moreover, of the compounds of the formula (I), those in which R^3 represents a carboxymethyl group (i.e., compound of the formula (Iq)) can be prepared by hydrolyzing the compound of the formula (Io) or (Ip). The hydrolysis reaction can be carried out in the absence of solvents or in a suitable solvent for example, water, lower alcohols such as methanol, ethanol and isopropanol, and acetic acid, in the presence of an acid or an alkali. As for the acid there can be illustrated mineral acids such as hydrochloric acid and sulfuric acid.

Examples of the alkali include sodium hydroxide, potassium hydroxide, potassium carbonate and sodium carbonate.

The acid or alkali can be used usually at least 1 mole per mole of the compound of the formula (Io) or (Ip). Usually, a large excess amount of the acid or alkali relative to the compound of the formula (Io) or (Ip) is used.

The reaction can be carried out usually at about room temperature to 150°C, preferably 50 to 100°C and completed generally in about 30 minutes to 10 hours. Further, of the compounds of the formula (I), those in which R^2 represents a hydroxy group can be prepared by hydrolyzing a compound of the formula (I) in which R^2 represents a lower alkoxy group under the same conditions as those under which the compounds of the formula (XV) or (Iib) are hydrolyzed.

The compounds of this invention represented by the formula (I) prepared as described above can form pharmaceutically acceptable salts with acids and this invention also includes within its scope such pharmaceutically acceptable salts. The pharmaceutically acceptable acids which can be used for the salt formation can be various inorganic acids, for example, hydrochloric acid, sulfuric acid, phosphoric acid and hydrobromic acid, or organic acids such as oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid and benzoic acid.

O 052 016

The compounds of the formula (I) can be converted into a corresponding salt when they have an acid group by reacting the acid group with a pharmaceutically acceptable basic compound. Examples of basic compounds are inorganic basic compounds such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate and sodium hydrogen carbonate.

5 As stated above, the salts of the compound of the formula (I) as used herein refers to acid addition salts thereof with pharmaceutically acceptable acids and basic compounds as well as quaternary ammonium salts thereof with halides such as lower alkyl halides.

The compounds of the formula (I) and the salts thereof obtained as described above can be isolated from the respective reaction mixtures upon completion of the reaction and purified by conventional
10 procedures, for example, solvent extraction, dilution method, precipitation, recrystallization, column chromatography and preparative thin layer chromatography.

As is apparent to those skilled in the art, the compounds of the formula (I) can exist in optically active forms and this invention includes such optical isomers within its scope.

In using the compounds of this invention of the formula (I) and the salts thereof as therapeutic
15 agents, these compounds can be formulated into pharmaceutical compositions together with ordinary pharmaceutically acceptable carriers. Suitable carriers which can be used are, for example, solvents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surface active agents and lubricants which are usually employed to prepare such drugs depending on the type of dosage form.

Various dosage forms of the therapeutic agents as a cardiotonic agent can be selected according
20 to the purpose of the therapy. Typical dosage forms which can be used are tablets, pills, powders, liquid preparations, suspensions, emulsions, granules, capsules, suppositories, and injectable preparations (e.g. solutions and suspensions).

In molding a pharmaceutical composition containing the compounds of the formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient into a tablet form, a wide range of
25 carriers known in the art can be used. Examples of suitable carriers include excipients such as lactose, white sugar, sodium chloride, glucose solution, urea, starch, calcium carbonate, kaolin, crystalline cellulose and silicic acid, binders such as water, ethanol, propanol, simple syrup, glucose, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and polyvinyl pyrrolidone, disintegrants such as dried starch, sodium alginate, agar powder, laminaria
30 powder, sodium hydrogen carbonate, calcium carbonate, Tween (Registered Trade Mark), sodium lauryl sulfate, stearic acid monoglyceride, starch, and lactose, disintegration inhibitors such as white sugar, stearic acid glyceryl ester, cacao butter and hydrogenated oils, absorption promoters such as quaternary ammonium bases and sodium lauryl sulfate, humectants such as glycerol and starch, adsorbents such as starch, lactose, kaolin, bentonite and colloidal silicic acid, and lubricants such as
35 purified talc, stearic acid salts, boric acid powder, Macrogol (Registered Trade Mark — a polyethylene glycol produced by Shinetsu Chemical Industry Co., Ltd.) and solid polyethylene glycol.

The tablets, if desired, can be coated, and made into sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, or tablets comprising two or more layers.

In molding the pharmaceutical composition into pills, a wide variety of conventional carriers
40 known in the art can be used. Examples of suitable carriers are excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oils, kaolin and talc, binders such as gum arabic powder, tragacanth powder, gelatin, and ethanol, and disintegrants such as laminaria and agar.

In molding the pharmaceutical composition into a suppository form, a wide variety of carriers known in the art can be used. Examples of suitable carriers include polyethylene glycol, cacao butter,
45 higher alcohols, esters of higher alcohols, gelatin, and semi-synthetic glycerides.

When the pharmaceutical composition is formulated into an injectable preparation, the resulting solution and suspension are preferably sterilized, and are isotonic with respect to the blood. In formulating the pharmaceutical composition into the form of a solution or suspension, all diluents customarily used in the art can be used. Examples of suitable diluents are water, ethyl alcohol,
50 propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, and sorbitan esters. Sodium chloride, glucose or glycerol may be incorporated into a therapeutic agent, e.g., as a nephritis treating agent in an amount sufficient to prepare isotonic solutions. The therapeutic agent may further contain ordinary dissolving aids, buffers, pain-alleviating agents, and preservatives, and optionally coloring agents, perfumes, flavors, sweeteners, and other drugs.

55 The amount of the compound of the formula (I) and the pharmaceutically acceptable salts thereof of this invention as an active ingredient to be incorporated into a pharmaceutical composition useful as a cardiac stimulant is not particularly limited, and can vary over a wide range. A suitable therapeutically effective amount of the compound of the general formula (I) and the pharmaceutically acceptable salts thereof of this invention is usually about 1 to about 70% by weight, preferably 5 to 50% by weight,
60 based on the entire composition.

There is no particular restriction on the manner of using the cardiotonic agent, and it can be administered by routes suitable for the particular forms thereof. For example, the tablets, pills, liquid preparations, suspensions, emulsions, granules, and capsules are orally administered. The injectable preparations are intravenously administered either alone or together with ordinary auxiliary agents such
65 as glucose and amino acids. Furthermore, as required, the cardiotonic agent can be singly administered

0 052 016

intramuscularly, intracutaneously, subcutaneously, or intraperitoneally. The suppository is administered intrarectally and the ointment is coated on the skin.

The dosage of the cardiotonic agent is suitably selected according to the purpose of use, the symptoms, etc. Usually, a preferred dosage of the compound of this invention is about 1 to 10 mg/kg body weight per day. It is advantageous that the active ingredient is contained in a single unit dose form in an amount of 50 to 250 mg.

This invention will be described in greater detail with reference to Reference Examples, Examples and Preparation Examples.

Reference Example 1

8-Hydroxy-3,4-dihydrocarbostyrl (20 g) was suspended in acetic anhydride (100 ml). Sulfuric acid (5 drops) was added to the resulting suspension and the mixture was stirred at 80°C for 1.5 hours. To the reaction mixture was added acetic acid (100 ml) and the mixture was ice-cooled, and a solution of 10.1 ml of concentrated nitric acid ($d=1.38$) in 30 ml of acetic anhydride was added thereto with stirring. The stirring was continued for one night at room temperature. The reaction mixture was poured into ice water to precipitate crystals, which were collected by filtration to give 21.74 g of 6-nitro-8-acetoxy-3,4-dihydrocarbostyrl.

m.p. above 300°C, pale yellow powders

NMR (DMSO- d_6):

δ (ppm) = 8.03 (d, $J=2.5$ Hz, 1H),

7.96 (d, $J=2.5$ Hz, 1H),

3.20~2.98 (m, 2H), 2.68~2.45

(m, 2H), 2.33 (s, 3H)

Reference Example 2

Hydrochloric acid (200 ml) was added to 6-nitro-8-acetoxy-3,4-dihydrocarbostyrl (20 g) and the mixture was refluxed for 4 hours. After ice cooling, crystals which precipitated were collected by filtration and recrystallized from methanol to give 13.76 g of 6-nitro-8-hydroxy-3,4-dihydrocarbostyrl.

m.p. 270°C, pale yellow scales.

Reference Example 3

6-Nitro-8-hydroxy-3,4-dihydrocarbostyrl (10 g) and potassium carbonate (13.3 g) were mixed with acetone (70 ml) and water (70 ml) and the mixture was refluxed with adding dropwise 12.1 g of dimethyl sulfate. After refluxing was continued for 4 hours, the reaction mixture was cooled, and crystals which precipitated were collected by filtration and washed with water to give 8.22 g of 6-nitro-8-methoxy-3,4-dihydrocarbostyrl.

m.p. 230°C, yellow needles.

Reference Example 4

6-Nitro-8-methoxy-3,4-dihydrocarbostyrl (2 g) and 5% palladium-carbon (0.2 g) were added in ethanol (50 ml) and catalytic reduction was conducted at a hydrogen gas pressure of 3 kg/cm² for 1 hour. Then, the reaction mixture was filtered and the filtrate was concentrated. The residue was recrystallized from benzene to give 1.7 g of 6-amino-8-methoxy-3,4-dihydrocarbostyrl.

m.p. 157—158°C, colorless needles.

Reference Example 5

To a mixture of 6-amino-8-methoxy-3,4-dihydrocarbostyrl (12 g), concentrated hydrochloric acid (16 ml) and water (50 ml) was added ice (30 g), and sodium nitrite (5 g) and water (20 ml) were added gradually to the resulting mixture under ice-cooling. After completion of addition, the resulting mixture was reacted at 0 to 5°C for 1 hour. On the other hand, a heated solution of acetaldehyde semicarbazide (10 g) in water (50 ml) and then sodium sulfite (0.25 g) and copper sulfate (3.2 g) were added to a solution of sodium acetate (34 g) in water (40 ml), and the internal bath was adjusted to a temperature of 10 to 20°C. The solution was stirred and below the surface of the solution was added gradually a solution prepared by adding a solution of sodium acetate (26 g) in water (46 ml) to the above diazonium salt solution. After stirring was continued for 2 hours, the reaction was allowed to stand for one night. Precipitates which formed were collected by filtration and washed with water. They were added in 200 ml of 2N hydrochloric acid and the mixture was refluxed for 2 hours. After cooling, the reaction mixture was extracted with chloroform (150 ml) twice and the chloroform layer was washed with water. The solution was filtered through a short column charged with silica gel-activated carbon. This column was washed with 500 ml of chloroform. The two chloroform layers were combined and

O 052 016

chloroform was evaporated. The residue was recrystallized from benzene to give 5.1 g of 6-acetyl-8-methoxy-3,4-dihydrocarbostyryl.

m.p. 150°C, pale yellow needles.

Reference Example 6

To a solution of 6-acetyl-8-methoxy-3,4-dihydrocarbostyryl (3.1 g) in chloroform (30 ml) was added dropwise a solution of bromine (2.26 g) in chloroform (20 ml) with stirring at room temperature. After completion of addition, the mixture was stirred for 30 minutes at room temperature, thereafter, the reaction mixture was concentrated and the residue was recrystallized from methanol to give 3.2 g of 6-(α -bromoacetyl)-8-methoxy-3,4-dihydrocarbostyryl.

m.p. 206—207°C, colorless needles.

Reference Example 7

To a solution of aluminum chloride (44 g) and α -bromo-propionyl chloride (43 g) in carbon disulfide (150 ml) was added portionwise 3,4-dihydrocarbostyryl (8 g) while refluxing with stirring. After completion of addition, the mixture was refluxed with stirring for 2 hours. After cooling, the mixture was poured into ice water and crystals which precipitated were collected by filtration and washed with water. Recrystallization from ethanol gave 14.2 g of 6-(α -bromo-propionyl)-3,4-dihydrocarbostyryl.

m.p. 192—193°C, pale yellow scales.

Reference Example 8

To a solution of aluminum chloride (80 g) and chloroacetyl chloride (72 g) in carbon disulfide (200 ml) was added portionwise, in 20 minutes a suspension of 3,4-dihydrocarbostyryl (14.7 g) in carbon disulfide (100 ml) while refluxing with stirring. After completion of addition, the mixture was refluxed with stirring for 2 hours. After cooling, the reaction mixture was poured into ice water, and crystals which precipitated were collected by filtration, washed with water and recrystallized from ethanol to give 20 g of 6-chloroacetyl-3,4-dihydrocarbostyryl.

m.p. 230—231°C, colorless needles.

Reference Example 9

In the same manner as in Reference Example 8 except that carbostyryl was used in place of 3,4-dihydrocarbostyryl, 6-chloroacetylcarbostyryl was obtained.

m.p. 275—277°C, pale green needles.

Reference Example 10

8-Methyl-3,4-dihydrocarbostyryl (16.1 g) was suspended in carbon disulfide (100 ml) and α -propionylbromide (35 g) was added to the suspension with stirring and cooling with ice water. Then, anhydrous aluminum chloride (30 g) was added portionwise to the mixture followed by refluxing for 3 hours. Under reduced pressure carbon disulfide was evaporated and the residue was decomposed by the addition of ice water (500 ml).

Tarry product which precipitated was separated and washed with water. A small amount of methanol was added to the tarry product to form crystals. The crystals were collected by filtration and recrystallized from methanol to give 14.3 g of 8-methyl-6- α -bromopropionyl-3,4-dihydrocarbostyryl.

m.p. 232.5—233.5°C, colorless needles.

Reference Example 11

To a solution of α -bromopropionylbromide (60 g) and aluminum chloride (40 g) in carbon disulfide (100 ml) was added 8-chloro-3,4-dihydrocarbostyryl (10 g). After refluxing the mixture for 5 hours, carbon disulfide was evaporated and heated at 70 to 80°C for 5 hours. The reaction mixture was poured into ice water and allowed to stand overnight. The mixture was extracted with chloroform and the chloroform layer was washed with water, dried and treated with activated carbon followed by evaporating chloroform. The residue was washed with diethyl ether and collected by filtration. The residue gave a uniform crystal fraction upon TLC. The crude crystals thus obtained were recrystallized from methanol to give 12 g of 8-chloro-6- α -bromopropionyl-3,4-dihydrocarbostyryl.

m.p. 180—182°C, pale yellow needles.

Reference Example 12

To a solution of 8-hydroxycarbostyryl (27 g) and chloroacetyl chloride (37 ml) in nitrobenzene

0 052 016

(250 ml) was added aluminum chloride (85 g) portionwise and the mixture was stirred at 70°C for 20 hours. After adding 10% hydrochloric acid (500 ml), nitrobenzene was removed by steam distillation. After cooling, crystals which formed were collected by filtration, washed with 300 ml of hot water and recrystallized from methanol to give 4.0 g of 5-chloroacetyl-8-hydroxycarbostyrl.

5

m.p. 285—287°C (decomp.), pale yellow crystals.

Example 1

6-(α -Bromopropionyl)-1-methyl-3,4-dihydrocarbostyrl (5 g), 2-aminopyridine (4.77 g) and acetonitrile (20 ml) were refluxed for 1.5 hours. The reaction mixture was cooled with ice water and crystals which precipitated were collected by filtration. The crystals were dissolved in acetone and the solution was adjusted to pH of about 1 by the addition of 48% hydrobromic acid. Crystals which formed were collected by filtration and recrystallized from water to give 5.68 g of 6-(3-methylimidazo[1,2-a]pyridine-2-yl)-1-methyl-3,4-dihydrocarbostyrl monohydrobromide.

15

m.p. above 300°C, colorless powders

NMR (DMSO- d_6)

δ (ppm) = 8.85 (d, $J=7$ Hz, 1H)

20

8.13—7.20 (m, 6H)

3.33 (s, 3H)

3.15~2.87 (m, 2H)

2.73 (s, 3H)

2.68~2.37 (m, 2H)

25

Example 2

8-Chloro-6-(α -bromopropionyl)-3,4-dihydrocarbostyrl (4 g), 2-aminopyridine (3.57 g) and acetonitrile (20 ml) were refluxed for 3 hours. The reaction mixture was concentrated to dryness and the residue (oily product) was washed with water. Then, the residue was dissolved in acetone and 48% hydrobromic acid was added to the solution to adjust pH to about 1 and crystals which formed were crystallized by filtration. The crude crystals thus obtained were recrystallized from water to give 2.74 g of 8-chloro-6-(3-methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrl monohydrobromide hemihydrate.

35

m.p. above 300°C, pale yellow powders

NMR (DMSO- d_6)

δ (ppm) = 9.78 (s, 1H)

40

8.83 (d, $J=7$ Hz, 1H)

8.03—7.43 (m, 5H)

3.23—2.97 (m, 2H)

2.74 (s, 3H)

2.70—2.43 (m, 2H)

45

Example 3

In an analogous manner as in Example 2, the following compounds were prepared using appropriate starting materials.

8-Methyl-6-(3-methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrl monohydrochloride monohydrate

50

m.p. 273—276°C (decomp.), pale yellow powders

6-(3-Methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrl monohydrobromide hemihydrate

55

m.p. above 300°C, pale yellow needles

NMR (DMSO- d_6 - D_2O)

δ (ppm) = 8.65 (d, $J=7$ Hz, 1H)

60

8.06—7.73 (m, 2H)

7.67—7.40 (m, 3H)

7.23—7.03 (m, 1H)

3.20—2.50 (m, 4H)

2.72 (s, 3H)

65

0 052 016

8-Methyl-6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl monohydrochloride 3/2 hydrate

m.p. above 300°C, pale brown crystals

5 NMR (DMSO- d_6)
 δ (ppm) = 9.64 (s, 1H)
8.86 (d, J=7Hz, 1H)
8.70 (s, 1H)
8.03—7.30 (m, 5H)
10 3.10—2.83 (m, 2H)
2.67—2.40 (m, 2H)
2.32 (s, 3H)

15 8-Chloro-6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl monohydrochloride hemihydrate

m.p. above 300°C, pale brown cottony crystals

20 NMR (DMSO- d_6)
 δ (ppm) = 9.70 (s, 1H)
8.82 (d, J=7Hz, 1H)
8.75 (s, 1H)
8.05—7.23 (m, 5H)
3.20—2.90 (m, 2H)
2.73—2.40 (m, 2H)

25 : 8-Methoxy-6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl monohydrobromide

m.p. 294.5—296.0°C (decomp.), pale yellow cottony crystals

30 6-(imidazo[1,2-a]pyridine-2-yl)carbostyryl monohydrochloride

m.p. above 300°C, pale yellow cottony crystals

35 NMR (DMSO- d_6)
 δ (ppm) = 8.74 (d, J=7Hz, 1H)
8.61 (s, 1H)
8.31 (d, J=2.5Hz)
8.17—7.10 (m, 6H)
6.58 (d, J=9Hz, 1H)

40 6-(3-Ethylimidazo[1,2-a]pyridine-2-yl)carbostyryl monohydrobromide monohydrate

m.p. above 300°C, colorless cottony crystals

45 NMR (DMSO- d_6 — D_2O)
 δ (ppm) = 8.81 (d, J=Hz, 1H)
8.14 (d, J=10Hz, 1H)
8.05—7.45 (m, 6H)
6.69 (d, J=10Hz, 1H)
50 3.45—3.00 (m, 2H)
1.38 (t, J=7.5Hz, 3H)

6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl

55 m.p. 230—232°C (decomp.), colorless powders

Example 4

To a suspension of 6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl (5 g) in dioxane (50 ml) 60 was added DDQ (6.47 g) with stirring at 70°C. The reaction mixture was heated for 5 hours with stirring. After completion of reaction, the solvent was evaporated. The residue was extracted by the addition of chloroform and 0.5 N sodium hydroxide. The chloroform layer was washed with 0.5 N sodium hydroxide, washed with water and dried. After evaporation chloroform, the residue obtained was isolated and purified using silica gel column chromatography. Oily product obtained was dissolved 65 in acetone and the solution was adjusted to pH of about 1 with concentrated hydrochloric acid. Crystals

O 052 016

which formed were collected by filtration. The crude crystals thus obtained were recrystallized from water to give 2.4 g of 6-(imidazo[1,2-a]pyridine-2-yl)carbostyrl monohydrochloride.

m.p. above 300°C, pale yellow cottony crystals

5

NMR (DMSO- d_6)

δ (ppm) = 8.74 (d, $J=7$ Hz, 1H)

8.61 (s, 1H)

8.31 (d, $J=2.5$ Hz)

10

8.17—7.10 (m, 6H)

6.58 (d, $J=9$ Hz, 1H)

Example 5

In an analogous manner as in Example 4, 6-(3-ethyl-imidazo[1,2-a]pyridine-2-yl)carbostyrl
15 monohydrobromide monohydrate was prepared using appropriate starting materials.

m.p. above 300°C, colorless cottony crystals

NMR (DMSO- d_6 - D_2O)

20

δ (ppm) = 8.81 (d, $J=7$ Hz, 1H)

8.14 (d, $J=10$ Hz, 1H)

8.05—7.45 (m, 6H)

6.69 (d, $J=10$ Hz, 1H)

3.45—3.00 (m, 2H)

25

1.38 (t, $J=7.5$ Hz, 3H)

Example 6

To a solution of 8-methyl-6-(3-methylimidazo[1,2-a]pyridine-2-yl)carbostyrl (2 g) in 40 ml of
methanol was added 10% palladium-carbon (0.2 g), and the mixture was subjected to catalytic
reduction at 60°C for 8 hours at a hydrogen gas pressure of 2 to 3 kg/cm². After completion of the
30 reaction the catalyst was removed by filtration and the filtrate was concentrated to dryness. The residue
was dissolved in acetone and the solution was adjusted to pH of about 1 with concentrated
hydrochloric acid. Crystals which precipitated were collected by filtration. The crude crystals thus
formed were recrystallized from ethanol to give 1.2 g of 8-methyl-6-(3-methylimidazo[1,2-a]pyridine-
2-yl)-3,4-dihydrocarbostyrl monohydrochloride monohydrate.

35

m.p. 273—276°C (decomp.), pale yellow needles

Example 7

In an analogous manner as in Example 6, the following compounds were prepared using
40 appropriate starting materials.

6-(3-Methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrl monohydrobromide hemihydrate

m.p. above 300°C, pale yellow needles

45

NMR (DMSO- d_6 - D_2O)

δ (ppm) = 8.65 (d, $J=7$ Hz, 1H)

8.06—7.73 (m, 2H)

7.67—7.40 (m, 3H)

50

7.23—7.03 (m, 1H)

3.20—2.50 (m, 4H)

2.72 (s, 3H)

8-Methyl-6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrl monohydrochloride 3/2 hydrate

55

m.p. above 300°C, pale brown powders

NMR (DMSO- d_6)

δ (ppm) = 9.64 (s, 1H)

60

8.86 (d, $J=7$ Hz, 1H)

8.70 (s, 1H)

8.03—7.30 (m, 5H)

3.10—2.83 (m, 2H)

2.67—2.40 (m, 2H)

65

2.32 (s, 3H)

O 052 016

8-Chloro-6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl monohydrochloride hemihydrate

m.p. above 300°C, pale brown cottony crystals

5 NMR (DMSO- d_6)
 δ (ppm) = 9.70 (s, 1H)
 8.82 (d, $J=7$ Hz, 1H)
 8.75 (s, 1H)
 8.05—7.23 (m, 5H)
 10 3.20—2.90 (m, 2H)
 2.73—2.40 (m, 2H)

6-(3-Methylimidazo[1,2-a]pyridine-2-yl)-1-methyl-3,4-dihydrocarbostyryl monohydrobromide

15 m.p. above 300°C, colorless powders

NMR (DMSO- d_6)
 δ (ppm) = 8.85 (d, $J=7$ Hz, 1H)
 8.13—7.20 (m, 6H)
 20 3.33 (s, 3H)
 3.15—2.87 (m, 2H)
 2.73 (s, 3H)
 2.68—2.37 (m, 2H)

25 8-Methoxy-6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl monohydrobromide

m.p. 294.5—296.0°C (decomp.), pale yellow cottony crystals

Example 8

30 To a solution of 6-(3-methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl (3 g) in dimethylformamide (50 ml) was added 50% oily sodium hydride (590 mg) and the mixture was reacted for 2 hours at room temperature. Then, after adding methyl iodide (1.85 g), the mixture was further reacted for 3 hours at room temperature. After completion of reaction, dimethylformamide was evaporated. Chloroform and 0.5 N sodium hydroxide were added to the residue for extraction. The chloroform layer
 35 was washed with water thoroughly and dried followed by evaporation of chloroform. The residue was purified using silica gel column chromatography and the oily product thus obtained was dissolved in acetone. The solution was adjusted to pH of about 1 by the addition of 48% hydrobromic acid and crystals which formed were collected by filtration. The crude crystals thus obtained were recrystallized from water to give 2.9 g of 6-(3-methyl-imidazo[1,2-a]pyridine-2-yl)-1-methyl-3,4-dihydrocarbostyryl
 40 monohydrobromide.

m.p. above 300°C, colorless powders

45 NMR (DMSO- d_6)
 δ (ppm) = 8.85 (d, $J=7$ Hz, 1H)
 8.13—7.20 (m, 6H)
 3.33 (s, 3H)
 3.15—2.87 (m, 2H)
 2.73 (s, 3H)
 50 2.68—2.37 (m, 2H)

Example 9

5-(α -bromobutyryl)-8-methoxy-3,4-dihydrocarbostyryl (5 g), 2-aminopyridine (4.33 g) and acetonitrile (20 ml) were reacted by refluxing for 6 hours. The reaction mixture was concentrated to dryness and the residue was crystallized by the addition of water. The crystals were collected by
 55 filtration and washed with water. The crystals were dissolved in acetone and the solution was adjusted to pH of about 1 to 2 by the addition of 48% hydrobromic acid. Crystals which formed were collected by filtration. The crude crystals thus obtained were recrystallized from methanol-ether to give 3.73 g of 5-(3-ethylimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrobromide.

60 m.p. 254—256.5°C, colorless powders

Example 10

5-Chloroacetyl-8-methoxycarbostyryl (5 g), 2-amino-4-picoline (6.45 g) and acetonitrile (40 ml)
 65 were reacted with refluxing for 3 hours; and the reaction mixture was cooled with ice water. Crystals

O 052 016

which formed were collected by filtration. The crystals were suspended in acetone-methanol and the suspension was adjusted to pH of about 1 by the addition of concentrated hydrochloric acid. Crystals which formed were collected by filtration and recrystallized from methanol to give 4.0 g of 5-(7-methylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride 3/2 hydrate.

m.p. 269.5—271.5°C (decomp.), colorless powders

Example 11

In an analogous manner as in Example 2, compounds shown below were prepared using appropriate starting materials.

- 5-(Imidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride monohydrate
m.p. 256—257.5°C (decomp.), colorless cottony crystals (water)
- 5-(Imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride hemihydrate
m.p. 260—261°C (decomp.), colorless needles (methanol)
- 5-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide 3/2 hydrate
m.p. 207.5—210.0°C, pale yellow scales (methanol-ether)
- 5-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrobromide
m.p. 263—264.5°C, pale yellow needles (methanol-ether)
- 5-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide 1/4 hydrate
m.p. 229—231.5°C, colorless powders (methanol-ether)
- 1-Methyl-5-(Imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride monohydrate
m.p. 259—260.5°C (decomp.), colorless needles (methanol-ether)
- 5-(6-Chloroimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride dihydrate
m.p. 270—272.5°C (decomp.), colorless powders (methanol-ether)
- 5-(8-Methylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride monohydrate
m.p. 255—258.0°C (decomp.), pale yellow cottony crystals (water)
- 5-(3,7-Dimethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide monohydrate
m.p. 249—251°C, colorless prisms (methanol-ether)
- 5-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-hydroxycarbostyryl monohydrochloride 1/4 hydrate
m.p. above 300°C, pale yellow cottony crystals (water)

Elemental analysis for $C_{18}H_{11}O_2N_3 \cdot HCl \cdot 1/4H_2O$

| | C | H | N |
|------------|-------|------|-------|
| Calc'd (%) | 60.38 | 3.96 | 13.21 |
| Found (%) | 60.55 | 3.80 | 13.23 |

NMR (DMSO — D_2O)

| |
|--------------------------------------|
| δ (ppm) = 8.82 (d, J=7.0, 1H) |
| 8.43 (s, 1H) |
| 8.18 (d, J=10.0, 1H) |
| 8.06—7.90 (m, 2H) |
| 7.63—7.43 (m, 1H) |
| 7.44 (d, J=8.0, 1H) |
| 7.23 (d, J=8.0, 1H) |
| 6.73 (d, J=10.0, 1H) |

5-(Imidazo[1,2-a]pyridine-2-yl)-8-hydroxy-3,4-dihydrocarbostyryl monohydrochloride 3/2 hydrate

m.p. above 300°C, colorless cottony crystals (water)

Elemental Analysis for $C_{16}H_{13}O_2N_3 \cdot HCl \cdot 3/2H_2O$

| | C | H | N |
|------------|-------|------|-------|
| Calc'd (%) | 56.06 | 5.00 | 12.26 |
| Found (%) | 55.82 | 4.91 | 12.34 |

O 052 016

NMR (DMSO)

δ (ppm) = 9.02 (s, 1H)
 8.93 (d, J=7.0, 1H)
 8.47 (s, 1H)
 8.10—7.80 (m, 2H)
 7.60—7.40 (m, 1H)
 7.23 (d, J=8.0, 1H)
 7.01 (d, J=8.0, 1H)
 3.26—2.97 (m, 2H)
 2.63—2.36 (m, 2H)

5-(3-Methyl-6-nitroimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide
 m.p. 247.5—250°C (decomp.), yellow needles (methanol-ether)

5-(3-Methyl-8-hydroxyimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride
 m.p. 266—268°C (decomp.), colorless powders (methanol-ether)

5-(8-Methoxyimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride 5/2 hydrate
 m.p. 215.0—216.5°C (decomp.), colorless cottony crystals (water)

5-(3-Methyl-6,8-dibromoimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide
 m.p. 246—247°C (decomp.), pale yellow needles (methanol)

1-Allyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride
 m.p. 250—252°C (decomp.), colorless needles (methanol-ether)

1-Benzyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride
 monohydrate
 m.p. 243.5—245.5°C (decomp.), colorless needles (ethanol)

1-Propargyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride
 hemihydrate
 m.p. 241.5—242.5°C (decomp.), colorless needles (ethanol)

Example 12

To a solution of 5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl (4 g) in acetic acid (80 ml) was added dropwise, at room temperature a solution of bromine (2.22 g) in acetic acid (5 ml). After completion of addition, the mixture was stirred for 3 hours. Crystals which precipitated were collected by filtration and washed with diethyl ether. The crystals thus obtained were dissolved in acetone and the solution was adjusted to pH of about 1 by the addition of 48% hydrobromic acid. Crystals which precipitated were collected by filtration and recrystallized from methanol-ether to give 5-(3-bromoimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide monohydrate

m.p. 245—247.5°C (decomp.), pale yellow needles

Example 13

To a suspension of 5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl (2.5 g) in 300 ml of water was added 1.71 ml of concentrated hydrochloric acid. The mixture was heated and the solution was cooled to 50°C and 10 ml of aqueous solution having dissolved therein 0.65 g of sodium nitrite was added dropwise to the solution at 50°C with stirring. After completion of addition, the reaction was continued for 2 hours and the reaction mixture was allowed to stand overnight at room temperature. Crystals which precipitated were collected by filtration, and recrystallized from methanol to give 1.9 g of (3-nitrosoimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl.

m.p. 236.5—238°C (decomp.), green cottony crystals

Example 14

To a suspension of 5-(3-nitrosoimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl (20.85 g) in methanol (500 ml) was added 12 ml of concentrated hydrochloric acid to render the suspension acidic. 10% Palladium-carbon (2 g) was added to the suspension, and catalytic reduction was carried out at room temperature under atmospheric pressure. After completion of reaction, water was added to the reaction mixture to dissolve and the resulting mixture was heated. After removing the catalyst by filtration, the filtrate was concentrated to dryness. Acetone was added to the residue, and crystals which precipitated were collected by filtration and recrystallized from water to give 21.20 g of 5-(3-aminoimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride hemihydrate.

m.p. 254.5—257.0°C (decomp.), pale yellow needles

Example 15

A solution of 5-(3-aminoimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl (5 g) in

O 052 016

90% formic acid (10 ml) was heated at 100°C for 2 hours. After completion of reaction, water was added to the reaction mixture followed by neutralizing with 1 N sodium hydroxide. Crystals which precipitated were collected by filtration, washed with methanol and recrystallized from chloroform-methanol to give 3.05 g of 5-(3-formylaminoimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl.

m.p. 303.5—305°C (decomp.), yellow prisms

Example 16

A mixture of 5-[3-aminoimidazo[1,2-a]pyridine-2-yl]-8-methoxy-3,4-dihydrocarbostyryl (5 g), 90% formic acid (15 ml) and 35% formalin (5 ml) was refluxed for 26 hours and the reaction mixture was concentrated to dryness. The residue was extracted by the addition of 1 N sodium hydroxide and chloroform. The chloroform layer was washed with water and dried followed by evaporating the solvent. The residue was passed through a silica gel column for isolation and crystals obtained were converted into hydrochloric acid salt in methanol. Recrystallization from methanol-ether gave 580 mg of 5-[3-dimethylaminoimidazo[1,2-a]pyridine-2-yl]-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride.

m.p. 242—244.5°C (decomp.), colorless prisms

Example 17

To a solution of 5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl (5 g) in acetic acid (50 ml) were added 50% aqueous solution of dimethylamine (1.7 g) and 35% aqueous solution of formalin (1.62 g). The mixture was stirred at 60°C for 6 hours. After evaporating the solvent, the residue was extracted by the addition of chloroform and 0.5 N sodium hydroxide. The chloroform layer was washed with water and dried followed by evaporating the solvent. The residue was dissolved in methanol and the solution was adjusted to pH of about 1 by the addition of concentrated hydrochloric acid and concentrated to dryness. Acetone was added to the residue to precipitate crystals, which were collected by filtration. The crude crystals thus obtained were recrystallized from methanol-acetone to give 5-(3-dimethylaminomethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl dihydrochloride trihydrate.

m.p. 213.5—216°C (decomp.), colorless cottony crystals

Example 18

To a suspension of 5-(3-dimethylaminomethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl (1.5 g) in acetonitrile (20 ml) was added methyl iodide (1.5 ml) and the mixture was stirred at 40°C for 1 hour. Crystals thus formed were collected by filtration and recrystallized from water to give 1.7 g of 5-(3-trimethylammoniomethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl iodide trihydrate.

m.p. 136—138°C (decomp.), pale yellow granules

Example 19

5-[3-Trimethylammoniomethylimidazo[1,2-a]pyridine-2-yl]-8-methoxycarbostyryl iodide (8 g) and sodium cyanide (3.2 g) were added to water (100 ml) and the mixture was refluxed for 5 hours. Crystals which precipitated were collected by filtration. After washing with methanol, the compound was converted into hydrochloric acid salt in methanol with concentrated hydrochloric acid and recrystallized from methanol-ether to give 3.6 g of 5-[3-carbamoylmethylimidazo[1,2-a]pyridine-2-yl]-8-methoxycarbostyryl monohydrochloride 5/4 hydrate.

m.p. 250.5—251.5 (decomp.), colorless needles

Example 20

A solution of 5-[3-trimethylammonioethylimidazo[1,2-a]pyridine-2-yl]-8-methoxycarbostyryl iodide (4.39 g) in water (40 ml) was refluxed while adding dropwise 10 ml of an aqueous solution of having dissolved therein 440 mg of sodium cyanide. After completion of addition, the mixture was reacted for 30 minutes and then allowed to cool. Crystals which precipitated were collected by filtration and isolated by passing through a silica gel column. The crude crystals thus formed were recrystallized from methanol to give 0.85 g of 5-[3-cyanomethylimidazo[1,2-a]pyridine-2-yl]-8-methoxycarbostyryl.

m.p. 261—263°C (decomp.), colorless prisms

Example 21

A mixture of 5-[3-carbamoylmethylimidazo[1,2-a]pyridine-2-yl]-8-methoxycarbostyryl (1.6 g), potassium hydroxide (2.6 g), water (3 ml) and ethanol (9 ml) was refluxed for 1 hour. After completion

O 052 016

of reaction water was added to the reaction mixture, which was then treated with activated carbon and adjusted to pH of about 1 by the addition of concentrated hydrochloric acid followed by allowing to stand overnight. Crystals which precipitated were collected by filtration and recrystallized from dilute hydrochloric acid to give 0.9 g of 5-[3-carboxymethylimidazo[1,2-a]pyridine-2-yl]-8-methoxycarbostyryl hemihydrate.

m.p. 259—260.5°C (decomp.), colorless needles

Example 22

5-(Imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl (1.4 g) and DDQ (3.5 g) were added to dioxane (30 ml) and the mixture was refluxed for 5 hours. The reaction mixture was concentrated under reduced pressure and the residue was extracted by the addition of chloroform and 0.5 N sodium hydroxide. The chloroform layer was washed with 0.5 N sodium hydroxide and then with water twice. After drying, chloroform was evaporated. The residue was isolated and purified through a silica gel column. The crude crystals thus obtained were dissolved in acetone and hydrochloric acid was added to the resulting solution. Crystals which precipitated were collected by filtration and recrystallized from water to give 410 mg of 5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride monohydrate.

m.p. 256—257.5°C (decomp.), colorless cottony crystals

Example 23

To a solution of 5 - (3 - ethylimidazo[1,2 - a]pyridine - 2 - yl) - 8 - methoxycarbostyryl (2 g) in methanol (50 ml) was added 10% palladium-carbon (0.2 g) and catalytic reduction was carried out for 6 hours at 50—60°C under a hydrogen gas pressure of 2 to 3 kg/cm². The catalyst was removed by filtration and the filtrate was concentrated to dryness. The residue was dissolved in acetone and hydrobromic acid was added to the solution. Crystals which precipitated were collected by filtration and the crude crystals thus obtained were recrystallized from methanol-ether to give 1.5 g of 5 - (3 - ethylimidazo[1,2 - a]pyridine - 2 - yl) - 8 - methoxy - 3,4 - dihydrocarbostyryl monohydrobromide.

m.p. 254—256.5°C, colorless powders

Example 24

To a solution of 5 - (imidazo[1,2 - a]pyridine - 2 - yl) - 8 - methoxy - 3,4 - dihydrocarbostyryl (3 g) in dimethylformamide (100 ml) was added 50% oily sodium hydride (600 mg) and the mixture was stirred for 2 hours at room temperature. After adding allyl bromide (1.48 g), the mixture was reacted for 3 hours at room temperature. The reaction mixture was concentrated to dryness and the residue was extracted by the addition of chloroform and 0.5 N sodium hydroxide. The chloroform layer was washed with water and dried followed by evaporation. The residue was purified using silica gel column chromatography and the oily product was dissolved in acetone and converted into hydrochloric acid salt by the addition of hydrochloric acid. Crystals which precipitated were collected by filtration and recrystallized from methanol-ether to give 1.76 g of 1 - allyl - 5 - (imidazo[1,2 - a]pyridine - 2 - yl) - 8 - methoxy - 3,4 - dihydrocarbostyryl monohydrochloride.

m.p. 250—252°C (decomp.), colorless needles

Example 25

In an analogous manner as in Example 24, the following compounds were prepared using appropriate starting materials.

1-Benzyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride monohydrate

m.p. 243.5—245.5 (decomp.), colorless needles (ethanol)

1-Propargyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride hemihydrate

m.p. 241.5—242.5°C (decomp.), colorless needles (ethanol)

1-Methyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride monohydrate

m.p. 259—260.5°C (decomp.), colorless needles (methanol-ether).

Example 26

In an analogous manner as in Examples 2 and 6, the following compounds were prepared using appropriate starting materials.

6 - (3,7 - Dimethylimidazo[1,2 - a]pyridine - 2 - yl)carbostyryl hydrochloride hemihydrate mp above 300°C, colorless needles (methanol)

O 052 016

NMR (DMSO-d₆)

δ (ppm) = 2.56 (s, 3H)
 2.67 (s, 3H)
 6.58 (d, J = 9Hz, 1H)
 7.34 (bd, J = 7Hz, 1H)
 7.49 (d, J = 8Hz, 1H)
 7.64 — 8.11 (m, 4H)
 8.59 (d, J = 7Hz, 1H)

6-(5-Methylimidazo[1,2-a]pyridine-2-yl)carbostyril hydrochloride.

m.p. above 300°C, pale yellow powder (methanol) NMR (CF₃—COOH)NMR (CF₃—COOH)

δ (ppm) = 2.94 (s, 3H)
 7.30 — 7.55 (m, 2H)
 7.83 — 8.17 (m, 3H)
 8.23 — 8.47 (m, 2H)
 8.53 (bs, 1H)
 8.70 (d, J = 9Hz, 1H)

6 - (3 - Dimethylaminomethylimidazo[1,2 - a]pyridine - 2 - yl)carbostyril dihydrochloride trihydrate. m.p. 204.5—207°C (decomp), colorless needles (water)

6 - (3 - Trimethylammoniomethylimidazo[1,2 - a]pyridine - 2 - yl)carbostyril iodide 3/4 hydrate. m.p. 185—188.5°C (decomp), colorless powder (methanol-acetone)
 6-(3-Nitrosoimidazo[1,2-a]pyridine-2-yl)carbostyril hemihydrate

m.p. above 300°C, yellowish-brown powder

NMR (CF₃ COOH)

δ (ppm) = 7.24 (d, J = 9Hz, 1H)
 7.83—8.07 (m, 2H)
 8.25 (d, J = 9Hz, 1H)
 8.43—8.77 (m, 2H)
 8.87 (dd, J = 9Hz, 2Hz, 1H)
 9.12 (d, J = 9Hz)
 9.88 (bd, J = 7Hz, 1H)

6-(3-Aminoimidazo[1,2-a]pyridine-2-yl)carbostyril

6-(Imidazo[1,2-a]pyridine-2-yl)-1-propargylcarbostyril hydrochloride 3/4 hydrate. m.p. 252—253°C (decomp.), colorless needles (water).

6-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyril hydrobromide hemihydrate. m.p. 314.5—318°C (decomp), colorless cottony (water)

6-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-1-allyl-3,4-dihydrocarbostyril hydrochloride, m.p. 279—282.5°C (decomp), colorless needles (ethanol)

6-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-1-propargyl-3,4-dihydrocarbostyril hydrochloride monohydrate, m.p. 264—265°C (decomp), colorless cottony (water)

6-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-1-propargylcarbostyril hydrochloride 1/4 hydrate. m.p. 265—266°C (decomp), colorless needles (water)

5-(8-Hydroxyimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyril monohydrochloride

m.p. 266.5—268.5°C (decomp.), colorless powders (methanol-ether)

Example 27

In an analogous manner as in Example 4, the following compounds were prepared using appropriate starting materials.

6-(3,7-Dimethylimidazo[1,2-a]pyridine-2-yl)carbostyril hydrochloride hemihydrate, m.p. above 300°C, colorless needles (methanol)

O 052 016

NMR (DMSO-d6)

δ (ppm) = 2.56 (s, 3H)
 2.67 (s, 3H)
 6.58 (d, J = 9Hz, 1H)
 7.34 (bd, J = 7Hz, 1H)
 7.49 (d, J = 8Hz, 1H)
 7.64—8.11 (m, 4H)
 8.59 (d, J = 7Hz, 1H)

6-(5-Methylimidazo[1,2-a]pyridine-2-yl)carbostyryl hydrochloride.

m.p. above 300°C, pale yellow powder (methanol)

NMR (CF₃—COOH)

δ (ppm) = 2.94 (s, 3H)
 7.30—7.55 (m, 2H)
 7.83—8.17 (m, 3H)
 8.23—8.47 (m, 2H)
 8.53 (bs, 1H)
 8.70 (d, J = 9Hz, 1H)

6-(3-Dimethylaminomethylimidazo[1,2-a]pyridine-2-yl)carbostyryl dihydrochloride trihydrate. m.p. 204.5—207°C (decomp.), colorless needles (water)

6-(3-Trimethylammoniomethylimidazo[1,2-a]pyridine-2-yl)-carbostyryl iodide 3/4 hydrate, m.p. 185—188.5°C (decomp) colorless needles (water)

6-(3-Nitrosoimidazo[1,2-a]pyridine-2-yl)carbostyryl hemihydrate

m.p. above 300°C, yellowish-brown powder

NMR (CF₃—COOH)

δ (ppm) = 7.24 (d, J = 9Hz, 1H)
 7.83—8.07 (m, 2H)
 8.25 (d, J = 9Hz, 1H)
 8.43—8.77 (m, 2H)
 8.87 (dd, J = 9Hz, 2Hz, 1H)
 9.12 (d, J = 9Hz)
 9.88 (bd, J = 7Hz, 1H)

6-(3-Aminoimidazo[1,2-a]pyridine-2-yl)carbostyryl

6-(Imidazo[1,2-a]pyridine-2-yl)-1-propargylcarbostyryl hydrochloride 3/4 hydrate. m.p.

252—253°C (decomp), colorless needles (water)

6-(3-ethylimidazo[1,2-a]pyridine-2-yl)-1-propargylcarbostyryl hydrochloride 1/4 hydrate. m.p.

265—266°C (decomp) colorless needles (water)

5-(8-Hydroxyimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride

m.p. 266.5—268.5°C (decomp.), colorless powders (methanol-ether)

Example 28

In an analogous manner as in Example 8, the following compounds were prepared using appropriate starting materials.

6-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-1-allyl-3,4-dihydrocarbostyryl hydrochloride. m.p.

278—282.5°C (decomp), colorless needles (ethanol)

6-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-1-propargyl-3,4-dihydrocarbostyryl hydrochloride

monohydrate. m.p. 264—265°C (decomp.), colorless cottony (water)

6-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-1-propargylcarbostyryl hydrochloride 1/4 hydrate. m.p.

265—266°C (decomp), colorless needles (water)

6-(Imidazo[1,2-a]pyridine-2-yl)-1-propargylcarbostyryl hydrochloride 3/4 hydrate. m.p.

252—253°C (decomp.), colorless needles (water)

Example 29

Pharmacological activity of the compounds of this invention was determined as described below.

1. Isolated blood-perfused sinoatrial node preparations

Experiments were carried out on adult mongrel dogs of either sex. The sinoatrial node preparations were obtained from dogs weighing 8—13 kg, anesthetized with pentobarbital sodium

O 052 016

(30 mg/kg i.v.), given heparin sodium (1000 U/kg i.v.) and exsanguinated. The preparation consisted essentially of the right atrium and was set up in cold Tyrode's solution. The preparation was placed in a glass water jacket maintained at about 38°C and cross-circulated through the cannulated right coronary artery with blood from a donor dog at a constant pressure of 100 mmHg. Dogs used as donors were 18—27 mg in body weight and were anesthetized with pentobarbital sodium (30 mg/kg i.v.). Heparin sodium was given at a dose of 1000 U/kg i.v. Tension developed by the right atrium was measured with a strain-gauge transducer. The right atrium was loaded with a weight of about 1.5 g. Sinus rate was measured by a cardiotachometer triggered by developed tension of the right atrium. Blood flow through the right coronary artery was measured by an electromagnetic flow meter. Recording of developed tension, sinus rate and blood flow was made on charts with an ink-writing rectigraph. Details of the preparation have been described by Chiba et al. (*Japan. J. Pharmacol.* 25, 433—439, 1975; *Naunyn-Schmiedberg's Arch. Pharmacol.* 289, 315—325, 1975). The compounds of 10—30 I were injected intra-arterially in 4 sec. The inotropic effects of the compounds are expressed as a percentage of the developed tension before the injection of the compounds. The effects of the compounds on sinus rate (beats/min) or blood flow (ml/min.) are expressed as a difference between the values before and after the injection of the compounds.

The results obtained are shown in Table 1 below.

Test Compounds

1. 6-(3-Methylimidazo[1,2-a]pyridine-2-yl)-1-methyl-3,4-dihydrocarbostyryl monohydrobromide
2. 8-Methoxy-4-(3-methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl monohydrochloride
3. 5-(3-Methyl-6,8-dibromoimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide
4. 1-Propargyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride hemihydrate
5. 5-(3,7-Dimethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide monohydrate
- a. Isoprenaline (Comparison)
- b. Amrinone (Comparison)
6. 5-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide 1/4 hydrate
7. 1-Methyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride
8. 5-(6-Chloroimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride dihydrate
9. 5-(7-Methylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride 3/2 hydrate
10. 5-(3-Dimethylaminoimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl dihydrochloride trihydrate
11. 1-Allyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride
12. 5-(Imidazo[1,2-a]pyridine-2-yl)-8-hydroxycarbostyryl monohydrochloride
13. 6-(Imidazo[1,2-a]pyridine-2-yl)carbostyryl monohydrochloride
14. 6-(3-Ethylimidazo[1,3-a]pyridine-2-yl)carbostyryl monohydrobromide monohydrate
15. 5-(3-Methyl-6-nitroimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl
16. 5-(3-Bromoimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide monohydrate
17. 5-(8-Hydroxyimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl
18. 5-(8-Methoxyimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride 5/2 hydrate
19. 5-(Imidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride
20. 6-(Imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl monohydrochloride
21. 6-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-methyl-3,4-dihydrocarbostyryl monohydrochloride monohydrate
22. 5-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrobromide
23. 5-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrobromide
24. 5-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrobromide hemihydrate
25. 5-(Imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrobromide hemihydrate
26. 6-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride 3/2 hydrate
27. 6-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-chloro-3,4-dihydrocarbostyryl monohydrobromide hemihydrate
28. 5-(3-Nitrosoimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl
29. 5-(3-Aminoimidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl monohydrochloride hemihydrate
30. 5-(3-Trimethylammoniomethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl iodide trihydrate
31. 5-(3-Carbamoylmethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl monohydrochloride 5/4 hydrate
32. 5-(3-Cyanomethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl
33. 5-(3-Carboxymethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl hemihydrate

O 052 016

TABLE 1

| Test Compound | Dose | % Change in Contraction of Atrial Muscle | Change in Rate of Coronary Blood Flow |
|---------------|--------------------|--|---------------------------------------|
| | (μ mole/l) | | (ml/min.) |
| 1 | 1 | 77.7 | 3.6 |
| 2 | 1 | 129.4 | 1.6 |
| 3 | 0.3 | 41.2 | 1.8 |
| 4 | 1 | 63.2 | 2.4 |
| 5 | 1 | 109.1 | 4.0 |
| a | 1×10^{-5} | 84.8 | 3 |
| b | 1 | 86.4 | 4.8 |
| 6 | 1 | 61.5 | 2 |
| 7 | 1 | 45.8 | 1.5 |
| 8 | 0.3 | 18.2 | 1.2 |
| 9 | 0.3 | 14.3 | — |
| 10 | 1 | 53.3 | 2.0 |
| 11 | 1 | 50.0 | 2.6 |
| 12 | 1 | 18.8 | 2.4 |
| 13 | 0.1 | 40.6 | 1.6 |
| 14 | 0.03 | 71.4 | 1.8 |
| 15 | 0.3 | 35.7 | 1.4 |
| 16 | 0.3 | 10.0 | — |
| 17 | 0.3 | 38.5 | 0.8 |
| 18 | 0.3 | 14.5 | — |
| 19 | 1 | 89.7 | 2.8 |
| 20 | 1 | 105 | 3.5 |
| 21 | 0.1 | 81.2 | 2.0 |
| 22 | 0.3 | 25 | 0.8 |
| 23 | 1 | 104.2 | 1.0 |
| 24 | 1 | 84.6 | 0.4 |
| 25 | 1 | 95 | 1.2 |
| 26 | 0.3 | 123.3 | 2.4 |
| 27 | 1 | 194.7 | 2.0 |

0 052 016

TABLE 1 (continued)

| 5 | Test Compound | Dose | % Change in Contraction of Atrial Muscle | Change in Rate of Coronary Blood Flow |
|----|---------------|-----------------|--|---------------------------------------|
| | | (μ mole/l) | | (ml/min.) |
| | 28 | 0.1 | 18.8 | — |
| 10 | 29 | 1 | 37 | 1.6 |
| | 30 | 0.3 | 40 | 0.6 |
| 15 | 31 | 0.3 | 13 | 0.8 |
| | 32 | 0.3 | 73 | 1.2 |
| | 33 | 0.1 | 20 | — |

Preparation Example 1

| | | |
|----|--|--------|
| | 8-Methoxy-(3-methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrl monohydrobromide | 5 mg |
| 25 | Starch | 132 mg |
| | Magnesium stearate | 18 mg |
| 30 | Lactose | 45 mg |
| | Total: | 200 mg |

In a conventional manner, tablets having the above composition were prepared.

Preparation Example 2

| | | |
|----|---|--------|
| | 6-(3-Methylimidazo[1,2-a]pyridine-2-yl)-1-methyl-3,4-dihydrocarbostyrl monohydrobromide | 10 mg |
| 40 | Starch | 127 mg |
| | Magnesium stearate | 18 mg |
| 45 | Lactose | 45 mg |
| | Total: | 200 mg |

In a conventional manner, tablets having the above composition were prepared.

Preparation Example 3

| | | |
|----|---|--------|
| | 8-Chloro-6-(3-methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrl monohydrobromide hemihydrate | 500 mg |
| 55 | Polyethylene glycol (Molecular weight: 4000) | 0.3 g |
| | Sodium chloride | 0.9 g |
| | Polyoxyethylene sorbitan monooleate | 0.4 g |
| 60 | Sodium metabisulfite | 0.1 g |
| | Methylparaben | 0.18 g |
| | Propylparaben | 0.02 g |
| 65 | Distilled water for injection | 100 ml |

© 052 016

The above parabens, sodium metabisulfite and sodium chloride were dissolved in the distilled water at 80°C while stirring. The resulting solution was cooled to 40°C and polyethylene glycol and polyoxyethylene sorbitan monooleate were dissolved therein. Then, distilled water for injection was added to adjust the volume to final one. The mixture was filtered using a suitable filter paper to sterilize and then filled in an ampoule of 1 ml, thus forming preparation for injection.

Preparation Example 4

| | | |
|----|--|--------|
| 10 | 1-Methyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyrl monohydrochloride monohydrate | 5 mg |
| | Starch | 132 mg |
| | Magnesium stearate | 18 mg |
| 15 | Lactose | 45 mg |
| | Total: | 200 mg |

20 Tablets each having the above composition were prepared in a conventional manner.

Preparation Example 5

| | | |
|----|---|--------|
| 25 | 5-(6-Chloroimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyrl monohydrochloride dihydrate | 10 mg |
| | Starch | 127 mg |
| | Magnesium stearate | 18 mg |
| 30 | Lactose | 45 mg |
| | Total: | 200 mg |

35 Tables each having the above composition were prepared in a conventional manner.

Preparation Example 6


| | | |
|----|---|--------|
| 40 | 5-(3,7-Dimethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyrl monohydrochloride monohydrate | 500 mg |
| | Polyethylene glycol (Molecular Weight: 4000) | 0.3 g |
| | Sodium chloride | 0.9 g |
| 45 | Polyoxyethylene sorbitan monooleate | 0.4 g |
| | Sodium metabisulfite | 0.1 g |
| 50 | Methylparaben | 0.18 g |
| | Propylparaben | 0.02 g |
| 55 | Distilled water for Injection | 100 ml |

The above parabens, sodium metabisulfite and sodium chloride were dissolved in the distilled water at 80°C while stirring. The resulting solution was cooled to 46°C and polyethylene glycol and polyoxyethylene sorbitan monooleate were dissolved therein. Then, distilled water for injection was added to adjust the volume to final one. The mixture was filtered using a suitable filter paper to sterilize and then filled in an ampoule of 1 ml, thus forming preparation for injection.

0 052 016

Claims

1. A carbostyryl compound of the formula (I)



wherein R¹ represents a hydrogen atom, a (C₁—C₆) alkyl group, a (C₂—C₆) alkenyl group, a (C₂—C₆) alkynyl group, or a phenyl-(C₁—C₆) alkyl group;


20 R² represents a hydrogen atom, a (C₁—C₆) alkyl group, a (C₁—C₆) alkoxy group, a halogen atom, or a hydroxy group;

R³ represents a hydrogen atom, a (C₁—C₆) alkyl group, a halogen atom, a nitroso group, an amino group which may be substituted with a (C₁—C₆) alkyl group, a (C₁—C₆) alkanoylamino group, an N,N-di-(C₁—C₆)alkylaminomethyl group, a carbamoylmethyl group, a cyanomethyl group, or a carboxy-methyl group;

25 R⁴ and R⁵, which may be the same or different, each represents a hydrogen atom, a halogen atom, a (C₁—C₆) alkyl group, a hydroxy group, a (C₁—C₆) alkoxy group, or a nitro group;

the bonding between the 3- and 4-positions of the carbostyryl nucleus is a single bond or a double bond; and


30 the position at which the imidazopyridyl group of the formula



is attached to the carbostyryl nucleus is the 5- or 6-position;


with the proviso that when the imidazopyridyl group is attached to the 5-position of the carbostyryl nucleus, R² should not be a hydrogen atom, a (C₁—C₆) alkyl group, or a halogen atom; or its pharmaceutically acceptable salt.

45 2. A compound or its pharmaceutically acceptable salt as claimed in Claim 1, wherein the substituent of the formula



is attached to the 5-position of the carbostyryl nucleus.

3. A compound or its pharmaceutically acceptable salt as claimed in Claim 1, wherein the substituent of the formula



34

O 052 016

is attached to the 6-position of the carbostyryl nucleus.

4. A compound or its pharmaceutically acceptable salt as claimed in Claim 2 or 3, wherein R¹ represents a hydrogen atom.

5. A compound or its pharmaceutically acceptable salt as claimed in Claim 2 or 3, wherein R¹ represents a (C₁—C₈) alkyl group, a phenyl-(C₁—C₈) alkyl group, a (C₂—C₈) alkenyl group, or a (C₂—C₈) alkynyl group.

6. 5-(3,7-Dimethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl or its pharmaceutically acceptable salt according to Claim 4.

7. 5-(3-Methyl-6-nitroimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl or its pharmaceutically acceptable salt according to Claim 4.

8. 5-(3-Ethylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl or its pharmaceutically acceptable salt according to Claim 4.

9. 1-Allyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl or its pharmaceutically acceptable salt according to Claim 5.

10. 1-Propargyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-methoxy-3,4-dihydrocarbostyryl or its pharmaceutically acceptable salt according to Claim 5.

11. 6-(Imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl or its pharmaceutically acceptable salt according to Claim 4.

12. 8-Chloro-6-(3-methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl or its pharmaceutically acceptable salt according to Claim 4.


13. 8-Methoxy-6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl or its pharmaceutically acceptable salt according to Claim 4.

14. 5-(3-Methylimidazo[1,2-a]pyridine-2-yl)-8-methoxycarbostyryl or its pharmaceutically acceptable salt according to Claim 4.

15. 8-Methyl-6-(3-methylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyryl or its pharmaceutically acceptable salt according to Claim 4.


16. 8-Methoxy-5-(imidazo[1,2-a]pyridine-2-yl)carbostyryl or its pharmaceutically acceptable salt according to Claim 4.

17. A process for preparing a carbostyryl compound of the formula (IA)




(IA)

wherein R⁶ represents a hydrogen atom or a (C₁—C₈) alkyl group and R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1; which comprises reacting a compound of the formula (II)



(II)

wherein X¹ represents a halogen atom and R¹, R² and R⁶ and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, with a compound of the formula (III)




(III)


0 052 016

wherein R^4 and R^5 have the same meanings as defined above, and optionally converting the product into its pharmaceutically acceptable salt.

18. A process for preparing a carbostyryl compound of the formula (If)




wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1 and X^6 represents a halogen atom; which comprises halogenating compound of the




wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above with a halogenating agent, and optionally converting the product into its pharmaceutically acceptable salt.

19. A process for preparing a carbostyryl compound of the formula (Ig)




wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1; which comprises nitrosylating a compound of the formula (Ie)




0 052 016

wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus having the same meanings as defined above with a nitrosylating agent and an acid in the absence of a solvent or in the presence of an inert solvent, and optionally converting the product into the pharmaceutically acceptable salt.

20. A process for preparing a carbostyryl compound of the formula (ii)




wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1; which comprises reducing a compound of the formula (ig)



wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, and optionally converting the product into its pharmaceutically acceptable salt.


21. A process for preparing a carbostyryl compound of the formula (ij)



wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as


0 052 016

defined in claim 1 and R^{11} represents a hydrogen atom or a (C_1-C_6) alkyl group; which comprises acylating a compound of the formula (ii)




wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above with an acylating agent, and optionally converting the product into its pharmaceutically acceptable salt.

22. A process for preparing a carbostyryl compound of the formula (Ik)




wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1, R^{11} represents a hydrogen atom and R^{12} represents a methyl group; which comprises reducing a compound of the formula (ii)




wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above by heating in the presence of formic acid and formalin in the absence of solvents, and optionally converting the product into its pharmaceutically acceptable salt.

23. A process for preparing a carbostyryl compound of the formula (II)



0 052 016

wherein R^1 , R^2 , R^4 , R^5 , X^2 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1, and R^{13} represents a (C_1-C_6) alkyl group; which comprises reacting a compound of the formula (li)




wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above; with a compound of the formula (XX)




wherein X^2 represents a halogen atom and R^{13} represents a (C_1-C_6) alkyl group, and optionally converting the product into its pharmaceutically acceptable salt.


24. A process for preparing a carbostyryl compound of the formula (Im)



wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1, and R^{14} and R^{15} , which may be the same or different, each represents a (C_1-C_6) alkyl group; which comprises reacting a compound of the formula (Ie)



wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, with a compound of the formula (XXI)




65 wherein R^{14} and R^{15} , which may be the same or different, each represents a (C_1-C_6) alkyl group and


0 052 016

formalin, and optionally converting the product into its pharmaceutically acceptable salt.

25. A process for preparing a carbostyryl compound of the formula (In)



wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1, R^{14} , R^{15} , and R^{16} , which may be the same or different, each represents a (C_1-C_6) alkyl group and M represents an alkali metal; which comprises reacting a compound of the formula (Im)




35 wherein R^1 , R^2 , R^4 , R^5 , R^{14} , R^{15} and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, with a compound of the formula (XXII)



wherein R^{16} represents a (C_1-C_6) alkyl group, and X^2 represents halogen, and optionally converting the product into its pharmaceutically acceptable salt.


26. A process for preparing a carbostyryl compound of the formula (Io)



wherein R^1 , R^2 , R^4 and R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus are

0 052 016

as defined in claim 1; comprising reacting a compound of the formula (In)




wherein R¹, R², R⁴, R⁵, R¹⁴, R¹⁵, R¹⁶ and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, with a compound of the formula (XXIII)




wherein M represents an alkali metal, and optionally converting the product in its pharmaceutically acceptable salt.

27. A process for preparing a carbostyryl compound of the formula (Ip)



wherein R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbostyryl nucleus are as defined in claim 1; which comprises reacting a compound of the formula (In)



wherein R¹, R², R⁴, R⁵, R¹⁴, R¹⁵, R¹⁶ and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, with a compound of the formula (XXIII)




wherein M represents an alkali metal, and optionally converting the product into its pharmaceutically acceptable salt.


65

0 052 016

28. A process for preparing a carbostyrl compound of the formula (Iq)




wherein R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbostyrl nucleus are as defined in claim 1; which comprises hydrolyzing a compound of the formula (Io)




wherein R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbostyrl nucleus have the same meanings as defined above, and optionally converting the product into its pharmaceutically acceptable salt.

29. A process for preparing a carbostyrl compound of the formula (Ip)



wherein R¹, R², R⁴, R⁵ and the bonding between the 3- and 4-positions of the carbostyrl nucleus are as defined in claim 1; which comprises hydrolyzing a compound of the formula (Ip)




O 052 016

wherein R^1 , R^2 , R^4 , R^5 and the bonding between the 3- and 4-positions of the carbostyryl nucleus have the same meanings as defined above, and optionally converting the product into its pharmaceutically acceptable salt.

30. A cardiotonic composition comprising a cardiotonically effective amount of a carbostyryl compound according to claim 1 or its pharmaceutically acceptable salt as active ingredient and a pharmaceutically acceptable carrier therefor.

Revendications

1. Un dérivé de carbostyryle de formule (I)




dans lequel R^1 représente un atome d'hydrogène, un groupe alkyle en C_1-C_6 , un groupe alcényle en C_2-C_6 , un groupe alcynyle en C_2-C_6 ou un groupe phényl-alkyle en C_1-C_6 ;

R^2 représente un atome d'hydrogène, un groupe alkyle en C_1-C_6 , un groupe alcoxy en C_1-C_6 , un atome d'halogène, ou un groupe hydroxy;


R^3 représente un atome d'hydrogène, un groupe alkyle en C_1-C_6 , un atome d'halogène, un groupe nitroso, un groupe amino qui peut être substitué par un groupe alkyle en C_1-C_6 , un groupe alcanoyl-amino en C_1-C_6 , un groupe N,N-di-(alkyl en C_1-C_6)-aminométhyle, un groupe carbamoylméthyle, un groupe cyanométhyle, ou un groupe carboxyméthyle;

R^4 et R^5 , qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe alkyle en C_1-C_6 , un groupe hydroxy, un groupe alcoxy en C_1-C_6 ou un groupe nitro; la liaison entre les position 3 et 4 du noyau carbostyryle est une liaison simple ou une liaison double; et la position à laquelle le groupe imidazopyridyle de formule



est fixé au noyau carbostyryle est la position 5 ou 6; avec la condition que, lorsque le groupe imidazopyridyle est attaché à la position 5 du noyau carbostyryle, R^2 ne doit pas être un atome d'hydrogène, un groupe alkyle inférieur, ou un atome d'halogène; ou son sel acceptable en pharmacie.


2. Un composé ou son sel acceptable en pharmacie comme revendiqué dans la revendication 1, dans lequel le substituant de formule



est fixé en position 5 du noyau carbostyryle.

0 052 016

3. Un composé ou son sel acceptable en pharmacie comme revendiqué dans la revendication 1, dans lequel le substituant de formule



est fixé en position 6 du noyau carbostyrile.

4. Un composé ou son sel acceptable en pharmacie comme revendiqué dans la revendication 2 ou 3, dans lequel R¹ représente un atome d'hydrogène.

15 Un composé ou son sel acceptable en pharmacie comme revendiqué dans la revendication 2 ou 3, dans lequel R¹ représente un groupe alkyle en C₁—C₈, un groupe phényl-alkyle en C₁—C₈, un groupe alcényle en C₂—C₈, ou un groupe alcynyle en C₂—C₈.

6. Le 5-(3,7-diméthylimidazo[1,2-a]pyridine-2-yl)-8-méthoxy-carbostyrile ou son sel acceptable en pharmacie selon la revendication 4.

20 7. Le 5-(3-méthyl-6-nitro-imidazo[1,2-a]pyridine-2-yl)-8-méthoxycarbostyrile ou son sel acceptable en pharmacie selon la revendication 4.

8. Le 5-(3-éthylimidazo[1,2-a]pyridine-2-yl)-8-méthoxycarbostyrile ou son sel acceptable en pharmacie selon la revendication 4.

9. Le 1-allyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-méthoxy-3,4-dihydrocarbostyrile ou son sel acceptable en pharmacie selon la revendication 5.

25 10. Le 1-propargyl-5-(imidazo[1,2-a]pyridine-2-yl)-8-méthoxy-3,4-dihydrocarbostyrile ou son sel acceptable en pharmacie selon la revendication 5.

11. Le 6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrile ou son sel acceptable en pharmacie selon la revendication 4.

30 12. Le 8-chloro-6-(3-méthylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrile ou son sel acceptable en pharmacie selon la revendication 4.


13. Le 8-méthoxy-6-(imidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrile ou son sel acceptable en pharmacie selon la revendication 4.

35 14. Le 5-(3-méthylimidazo[1,2-a]pyridine-2-yl)-8-méthoxycarbostyrile ou son sel acceptable en pharmacie selon la revendication 4.


15. Le 8-méthyl-6-(3-méthylimidazo[1,2-a]pyridine-2-yl)-3,4-dihydrocarbostyrile ou son sel acceptable en pharmacie selon la revendication 4.

16. Le 8-méthoxy-5-(imidazo[1,2-a]pyridine-2-yl)carbostyrile ou son sel acceptable en pharmacie selon la revendication 4.

40 17. Un procédé pour préparer un dérivé de carbostyrile de formule (IA)




55 dans laquelle R⁶ représente un atome d'hydrogène ou un groupe alkyle en C₁—C₈ et R¹, R², R⁴, R⁵ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1 qui consiste à faire réagir un composé de formule (II)




0 052 016

dans laquelle X^1 représente un atome d'halogène et R^1 , R^2 , R^6 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus, avec un composé de formule (III)




10 dans laquelle R^4 et R^5 sont comme définis ci-dessus, et à transformer facultativement le produit en son sel acceptable en pharmacie.

18. Un procédé pour préparer un dérivé de carbostyrile de formule (If)




25 dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1 et X^6 représente un atome d'halogène qui consiste à halogéner un composé de formule (Ie)



45 dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus et à transformer facultativement le produit en son sel acceptable en pharmacie.


19. Un procédé pour préparer un dérivé de carbostyrile de formule (Ig)



65 dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme


0 052.016

définis à la revendication 1 qui consiste à nitrosyler un composé de formule (Ie)




dans laquelle R¹, R², R⁴, R⁵ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus avec un agent de nitrosylation et un acide en l'absence de solvant ou en présence d'un solvant inerte, et à transformer facultativement le produit en son sel acceptable en pharmacie.

20. Un procédé pour préparer un dérivé de carbostyrile de formule (II)




35 dans laquelle R¹, R², R⁴, R⁵ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1 qui consiste à réduire un composé de formule (Ig)




50 dans laquelle R¹, R², R⁴, R⁵ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus, et à transformer facultativement le produit en son sel acceptable en pharmacie.

21. Un procédé pour préparer un dérivé de carbostyrile de formule (Ij)




0 052 016.

dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1 et R^{11} représente un atome d'hydrogène ou un groupe alkyle en C_1-C_6 , qui consiste à acyler un composé de formule (II)




dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus, avec un agent acylant et à transformer facultativement le produit en son sel acceptable en pharmacie.

22. Un procédé pour préparer un dérivé de carbostyrile de formule (Ik)



dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1, R^{11} représente un atome d'hydrogène et R^{12} représente un groupe méthyle, qui consiste à réduire un composé de formule (II)




55 dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus, par chauffage en présence d'acide formique et de formaline, en l'absence de solvants, et à transformer facultativement le produit en son sel acceptable en pharmacie.

60


65

O 052 016


23. Un procédé pour préparer un dérivé de carbostyrile de formule (II)



dans laquelle R^1 , R^2 , R^4 , R^5 , X^2 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1 et R^{13} représente un groupe alkyle en C_1-C_6 , qui consiste à faire réagir un composé de formule (II)




dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus; avec un composé de formule (XX)



dans laquelle X^2 représente un atome d'halogène et R^{13} représente un groupe alkyle en C_1-C_6 , et à transformer facultativement le produit en son sel acceptable en pharmacie.


24. Un procédé pour préparer un dérivé de carbostyrile de formule (Im)




dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1, et R^{14} et R^{15} peuvent être identiques ou différents et représentent chacun

0 052 016

un groupe alkyle en C_1-C_6 , qui consiste à faire réagir un composé de formula (Ie)




dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus, avec un composé de formule (XXI)




25 dans laquelle R^{14} et R^{15} peuvent être identiques ou différents et représentent chacun un groupe alkyle en C_1-C_6 et la formaline, et à transformer facultativement le produit en son sel acceptable en pharmacie.

25. Un procédé pour préparer un dérivé de carbostyrile de formule (In)



45 dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1, R^{14} , R^{15} , et R^{16} peuvent être identiques ou différents et représentent chacun un groupe alkyle en C_1-C_6 et M représente un métal alcalin que consiste à faire réagir un composé de formule (Im)




dans laquelle R^1 , R^2 , R^4 , R^5 , R^{14} , R^{15} et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus avec un composé de formule (XXII)




0 052 016

dans laquelle R^{16} représente un groupe alkyle en C_1-C_6 et X^2 représente un halogène, et à transformer facultativement le produit en son sel acceptable en pharmacie.

26. Un procédé pour préparer un dérivé de carbostyryle de formule (Io)



20 dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyryle sont comme définis à la revendication 1, qui consiste à faire réagir un composé de formule (In)




35 dans laquelle R^1 , R^2 , R^4 , R^5 , R^{14} , R^{15} , R^{16} et la liaison entre les positions 3 et 4 du noyau carbostyryle sont comme définis ci-dessus, avec un composé de formule (XXIII)

MCN (XXIII)

40 dans laquelle M représente un métal alcalin, et à transformer facultativement le produit en son sel acceptable en pharmacie.

27. Un procédé pour préparer un dérivé de carbostyryle de formule (Ip)




60 dans laquelle R^1 , R^2 , R^4 , R^5 et la liaison entre les positions 3 et 4 du noyau carbostyryle sont comme

60

65

0 052 016

définis à la revendication 1 qui consiste à faire réagir un composé de formule (In)




dans laquelle R¹, R², R⁴, R⁵, R¹⁴, R¹⁵, R¹⁶ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus, avec un composé de formule (XXIII)




dans laquelle M représente un métal alcalin, et à transformer facultativement le produit en son sel acceptable en pharmacie.

28. Un procédé pour préparer un dérivé de carbostyrile de formule (Iq)



dans laquelle R¹, R², R⁴, R⁵ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1, qui consiste à hydrolyser un composé de formule (Io).




55 dans laquelle R¹, R², R⁴, R⁵ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus, et à transformer facultativement le produit en son sel acceptable en pharmacie.

60


65

0 052 016

29. Un procédé pour préparer un dérivé de carbostyrile de formule (Iq)



dans laquelle R¹, R², R⁴, R⁵ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis à la revendication 1, qui consiste à hydrolyser un composé de formule (Ip)




dans laquelle R¹, R², R⁴, R⁵ et la liaison entre les positions 3 et 4 du noyau carbostyrile sont comme définis ci-dessus, et à transformer facultativement le produit en son sel acceptable en pharmacie.

30. Un composition cardiotonique consistant en une quantité efficace comme cardiotonique d'un dérivé de carbostyrile selon la revendication 1 ou son sel acceptable en pharmacie comme ingrédient actif et un support acceptable en pharmacie.

Patentansprüche

1. Carbostyrylverbindung der Formel (I)



worin bedeuten:


R¹ ein Wasserstoffatom, eine C₁₋₆-Alkylgruppe, eine C₂₋₆-Alkenylgruppe, eine C₂₋₆-Alkynylgruppe oder eine Phenyl-C₁₋₆-alkylgruppe;

R² ein Wasserstoffatom, eine C₁₋₆-Alkylgruppe, eine C₁₋₆-Alkoxygruppe, ein Halogenatom oder eine Hydroxygruppe,


R³ ein Wasserstoffatom, eine C₁₋₆-Alkylgruppe, ein Halogenatom, eine Nitrosogruppe, eine Aminogruppe, die durch eine C₁₋₆-alkylgruppe substituiert sein kann, eine C₁₋₆-Alkanoylaminogruppe, eine N,N-Di-C₁₋₆-alkylaminomethylgruppe, eine Carbamoylmethylgruppe, eine Cyanomethylgruppe oder eine Carboxymethylgruppe,

0 052 016.

R⁴ und R⁵, die gleich oder verschieden sein können, jeweils ein Wasserstoffatom, ein Halogenatom, eine C₁₋₆-Alkylgruppe, eine Hydroxygruppe, eine C₁₋₆-Alkoxygruppe oder eine Nitrogruppe, wobei die Bindung zwischen der 3- und 4-Stellung im Carbostyrilkern eine Einfach- oder Doppelbindung ist, und die Stellung, in welcher die Imidazopyridylgruppe der Formel




am Carbostyrilkern gebunden ist, die 5- oder 6-Stellung ist, mit dem Vorzeichen, dass dann, wenn die Imidazopyridylgruppe in der 5-Stellung des Carbostyrilkerns gebunden ist, R² kein Wasserstoffatom, keine C₁₋₆-Alkylgruppe oder kein Halogenatom ist; oder dessen pharmazeutisch annehmbaren Salze.
2. Verbindung oder deren pharmazeutisch annehmbaren Salz gemäß Anspruch 1, in welcher der Substituent der Formel



in der 5-Stellung des Carbostyrilkerns gebunden ist.

3. Verbindung oder deren pharmazeutisch annehmbares Salz gemäß Anspruch 1, worin der Substituent der Formel



in der 6-Stellung des Carbostyrilkerns gebunden ist.

4. Verbindung oder deren pharmazeutisch annehmbares Salz gemäß Ansprüchen 2 oder 3, worin R¹ ein Wasserstoffatom bedeutet.

5. Verbindung oder deren pharmazeutisch annehmbares Salz gemäß Anspruch 2 oder 3, worin R¹ eine C₁₋₆-Alkylgruppe, eine Phenyl-C₁₋₆-alkylgruppe, eine C₂₋₆-Alkenylgruppe oder eine C₂₋₆-Alkynylgruppe bedeutet.

6. 5-(3,7-Dimethylimidazo[1,2-a]pyridin-2-yl)-8-methoxy-carbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 4.

7. 5-(3-Methyl-6-nitroimidazo[1,2-a]pyridin-2-yl)-8-methoxycarbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 4.

8. 5-(3-Ethylimidazo[1,2-a]pyridin-2-yl)-8-methoxycarbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 4.

9. 1-Allyl-5-imidazo[1,2-a]pyridin-2-yl)-8-methoxy-3,4-dihydrocarbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 5.

10. 1-Propargyl-5-(imidazo[1,2-a]pyridin-2-yl)-8-methoxy-3,4-dihydrocarbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 5.

11. 6-Imidazo[1,2-a]pyridin-2-yl)-3,4-dihydrocarbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 4.

12. 8-Chlor-6-(3-methylimidazo[1,2-a]pyridin-2-yl)-3,4-dihydrocarbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 4.

13. 8-Methoxy-6-(imidazo[1,2-a]pyridin-2-yl)-3,4-dihydrocarbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 4.


14. 5-(3-Methylimidazo[1,2-a]pyridin-2-yl)-8-methoxycarbostyril oder dessen pharmazeutisch annehmbares Salz gemäß Anspruch 4.

0 052 016


15. 8-Methyl-6-(3-methylimidazo[1,2-a]pyridin-2-yl)3,4-dihydrocarbostyryl oder dessen pharmazeutisch annehmbares Salz gemäss Anspruch 4.

16. 8-Methoxy-5-(imidazo[1,2-a]pyridin-2-yl)-carbostyryl oder dessen pharmazeutisch annehmbares Salz gemäss Anspruch 4.


5 17. Verfahren zur Herstellung einer Carbostyrylverbindung der Formel (IA)



20 worin R⁶ ein Wasserstoffatom oder eine C₁₋₆-Alkylgruppe ist und R¹, R², R⁴, R⁵ und die Doppelbindung zwischen der 3- und 4-Stellung des Carbostyrylkerns die in Anspruch 1 angegebenen Bedeutungen haben, dadurch gekennzeichnet, dass man eine Verbindung der Formel (II)




35 worin X¹ ein Halogenatom ist und R¹, R² und R⁶ und die Bindung zwischen der 3- und 4-Stellung im Carbostyrylkern die vorher angegebenen Bedeutungen haben, mit einer Verbindung der Formel (III)



45 worin R⁴ und R⁵ die vorher angegebenen Bedeutungen haben, umgesetzt und gewünschtenfalls das Produkt in ein pharmazeutisch annehmbares Salz überführt.


18. Verfahren zur Herstellung einer Carbostyrylverbindung der Formel (If)



65 worin R¹, R², R⁴, R⁵ und die Bindung zwischen der 3- und 4-Stellung im Carbostyrylkern die in Anspruch 1 angegebenen Bedeutungen haben und X⁶ ein Halogenatom bedeutet, dadurch gekennzeichnet, dass


0 052 016

man eine Verbindung der Formel (Ie)




15 worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carboxystyrylkern die vorher angegebenen Bedeutungen haben, mit einem Halogenierungsmittel halogeniert und gewünschtenfalls das Produkt in ein pharmazeutisch annehmbares Salz überführt.

19. Verfahren zur Herstellung einer Carboxystyrylverbindung der Formel (Ig)




worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carboxystyrylkern die in Anspruch 1 angegebenen Bedeutungen haben, dadurch gekennzeichnet, dass man eine Verbindung der Formel (Ie)




50 worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carboxystyrylkern die vorher angegebenen Bedeutungen haben, mit einem Nitrosylierungsmittel und einer Säure, in Abwesenheit eines Lösungsmittels oder in Gegenwart eines inerten Lösungsmittels, nitrosyliert und gewünschtenfalls das Produkt in ein pharmazeutisch annehmbares Salz überführt.

20. Verfahren zur Herstellung einer Carboxystyrylverbindung der Formel (II)




0 052 016

worin R^1 , R^2 , R^4 und R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die in Anspruch 1 angegebenen Bedeutungen haben, dadurch gekennzeichnet, dass man eine Verbindung der Formel (Ig)




worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die vorher angegebenen Bedeutungen haben, reduziert und gegebenenfalls das Produkt in ein pharmazeutisch annehmbares Salz überführt.

21. Verfahren zur Herstellung einer Carbostrylverbindung der Formel (Ij)



worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die in Anspruch 1 angegebenen Bedeutungen haben und R^{11} ein Wasserstoffatom oder eine C_{1-6} -Alkylgruppe bedeutet, dadurch gekennzeichnet, dass man eine Verbindung der Formel (Ii)




55 in welcher R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die vorher angegebenen Bedeutungen haben, mit einem Acylierungsmittel acyliert und gegebenenfalls das Produkt in sein pharmazeutisch annehmbares Salz überführt.

60


65

0 052 016

22. Verfahren zur Herstellung einer Carbostyrilverbindung der Formel (Ik)




15 worin R¹, R², R⁴, R⁵ und die Bindung zwischen der 3- und 4-Stellung im Carbostyrilkern die in Anspruch 1 angegeben Bedeutungen haben, R¹¹ ein Wasserstoffatom und R¹² eine Methylgruppe bedeuten, dadurch gekennzeichnet, dass man eine Verbindung der Formel (ii)




in welcher R¹, R², R⁴, R⁵ und die Bindung zwischen der 3- und 4-Stellung im Carbostyrilkern die vorher angegebenen Bedeutungen haben, durch Erwärmen in Gegenwart von Ameisensäure und Formalin in Abwesenheit von Lösungsmittel reduziert und gewünschtenfalls das Produkt in sein pharmazeutisch

35 annehmbares Salz überführt.

23. Verfahren zur Herstellung einer Carbostyrilverbindung der Formel (II)



50 worin R¹, R², R⁴, R⁵, X² und die Bindung zwischen der 3- und 4-Stellung im Carbostyrilkern die in Anspruch 1 angegebenen Bedeutungen haben und R¹³ eine C₁₋₆-Alkylgruppe bedeutet, dadurch gekennzeichnet, dass man eine Verbindung der Formel (ii)



0 052 016


worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylriern die vorher angegebenen Bedeutungen haben, mit einer Verbindung der Formel (XX)



(XX)


worin X^2 ein Halogenatom und R^{13} eine C_{1-6} -Alkylgruppe bedeuten, umgesetzt und gewünschtenfalls das Produkt in sein pharmazeutisch annehmbares Salz überführt.

24. Verfahren zur Herstellung einer Carbostrylverbindung der Formel (Im)




(Im)

worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylriern die in Anspruch 1 angegebenen Bedeutungen haben und R^{14} und R^{15} , die gleich oder verschieden sein können, jeweils eine C_{1-6} -Alkylgruppe bedeuten, dadurch gekennzeichnet, dass man eine Verbindung der Formel (Ie)



(Ie)


worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylriern die vorher angegebenen Bedeutungen haben, mit einer Verbindung der Formel (XXI)



(XXI)

worin R^{14} und R^{15} , die gleich oder Verschieden sein könne, jeweils eine C_{1-6} -Alkylgruppe bedeuten, und Formalin umgesetzt und gewünschtenfalls das Produkt in sein pharmazeutisch annehmbares Salz überführt.


25. Verfahren zur Herstellung einer Carbostrylverbindung der Formel (In)



(In)

0 052 016

worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die in Anspruch 1 angegebenen Bedeutungen haben, R^{14} , R^{15} und R^{16} , die gleich oder verschieden sein können, jeweils ein C_{1-6} -Alkylgruppe und M ein Alkalimetall bedeuten, dadurch gekennzeichnet, dass man eine Verbindung der Formel (Im)




worin R^1 , R^2 , R^4 , R^5 , R^{14} , R^{15} und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die vorher angegebenen Bedeutungen haben, mit einer Verbindung der Formel (XXII)




worin R^{16} eine C_{1-6} -Alkylgruppe und X^2 ein Halogen bedeuten, umgesetzt und gewünschtenfalls das Produkt in sein pharmazeutisch annehmbares Salz überführt.

26. Verfahren zur Herstellung einer Carbostrylverbindung der Formel (Io)



worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die in Anspruch 1 angegebenen Bedeutungen haben, dadurch gekennzeichnet, dass man eine Verbindung der Formel (In)




worin R^1 , R^2 , R^4 , R^5 , R^{14} , R^{15} , R^{16} und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die vorher angegebenen Bedeutungen haben, mit einer Verbindung der Formel (XXIII)




worin M ein Alkalimetall bedeutet, umgesetzt und gewünschtenfalls das Produkt in sein pharmazeutisch annehmbares Salz überführt.

0 052 016

27. Verfahren zur Herstellung einer Carbostyrylverbindung der Formel (Ip)



15 worin R¹, R², R⁴, R⁵ und die Bindung zwischen der 3- und 4-Stellung im Carbostyrylkern die in Anspruch 1 angegebenen Bedeutungen haben, dadurch gekennzeichnet, dass man eine Verbindung der Formel (In)




30 worin R¹, R², R⁴, R⁵, R¹⁴, R¹⁵, R¹⁶ und die Bindung zwischen der 3- und 4-Stellung im Carbostyrylkern die vorher angegebenen Bedeutungen haben, mit einer Verbindung der Formel (XXIII)


MCN (XXIII)

35 worin M ein Alkalimetall bedeutet, umgesetzt und gewünschtenfalls das Produkt in sein pharmazeutisch annehmbares Salz überführt.

28. Verfahren zur Herstellung einer Carbostyrylverbindung der Formel (Iq)



50 worin R¹, R², R⁴, R⁵ und die Bindung zwischen der 3- und 4-Stellung im Carbostyrylkern die in Anspruch 1 angegebenen Bedeutungen haben, dadurch gekennzeichnet, dass man eine Verbindung der Formel (Io)



0 052 016


worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die vorher angegebenen Bedeutungen haben, hydrolysiert und gewünschtenfalls das Produkt in sein pharmazeutisch annehmbares Salz überführt.

29. Verfahren zur Herstellung einer Carbostrylverbindung der Formel (Iq)

5

10

15




(Iq)

20 worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die in Anspruch 1 angegebenen Bedeutungen haben, dadurch gekennzeichnet, dass man eine Verbindung der Formel (Ip)

25

30

35



(Ip)

worin R^1 , R^2 , R^4 , R^5 und die Bindung zwischen der 3- und 4-Stellung im Carbostrylkern die vorher angegebenen Bedeutungen haben, hydrolysiert und gewünschtenfalls das Produkt in sein pharmazeutisch annehmbares Salz überführt.

40 30. Kardiotonische Zusammensetzung, enthaltend eine kardiotonisch wirksame Menge einer Carbostrylverbindung gemäss Anspruch 1 oder dessen pharmazeutisch annehmbares Salz als aktiven Bestandteil und einen pharmazeutisch annehmbaren Träger hierfür.

45

50

55

60

65